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Abstract 
 
Colorectal Cancer is the third most common cancer and the second leading cause of death 
by cancer worldwide with about 1.3 million new cancer cases and 693,933 deaths reported 
in 2012. 
Here, we intend to determine an epigenetic roadmap of Colorectal Cancer to predict tumor 
progression and patient outcome. 
We analyzed whole-genome DNA methylation (Illumina Infinium HumanMethylation 
450K array) and gene expression (Illumina HiSeq) in multiple stages of CRC (21 normal, 
54 stage I, 131 stage II, 111 stage III, and 51 stage IV). The data is available in TCGA 
database, and was downloaded, processed and analyzed through R programming. 
Results show that, in stages I, II, III, and IV, 307, 400, 305 and 233 genes are differentially 
expressed (fold-change absolute value > 1.5, p-value adjusted<0.05) and 924, 1814, 1169, 
and 618 CpG sites are differentially methylated (Δβ absolute value > 0.2, p-value 
adjusted<0.05), respectively. In addition, all these CpG sites are correlated with the 
respective gene. When the KEGG and Gene Ontology analysis was performed, we found 
that the enriched functions are related to nervous system, one of the processes deregulated 
in cancer progression. Moreover, we also identified 66, 85, 41, and 40 specific genes for 
stages I, II, III, and IV, respectively. 
Regarding the diagnosis, were found 238 genes and 835 CpG sites as good diagnosis tool 
for stage I (AUC>0.8). Furthermore, 6, 1, and 5 genes and 87, 7, and 3 CpG sites were 
classified as good biomarkers for overall survival for stages I-IV, respectively. In 
addition, 3, 3, and 2 genes and 30, 12, 9 CpG sites were identified as good biomarkers for 
recurrence free survival for stages I-IV, respectively. 
These results suggest that different methylation events are associated to specific stages of 
CRC which can predict patient outcome and might improve colorectal cancer diagnosis 
and prognosis. 
 
Keywords: Colorectal Cancer, Epigenetics, DNA methylation, Biomarkers, Diagnosis, 
Prognosis.  
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Resumo 
Introdução: O cancro colorretal é um evento biológico que compreende múltiplos 
passos, decorrendo de diversas alterações genéticas e epigenéticas.  
Apesar das melhorias no rastreio, diagnóstico e prognóstico de cancro, incluindo de 
cancro colorretal, este continua a ser o terceiro tipo de cancro mais comum em homens e 
segundo em mulheres, com mais de 1,3 milhões de novos casos diagnosticados, e 693.933 
mortes reportados em todo o mundo no ano de 2012. Em parte, a incidência e mortalidade 
continuam elevadas devido à baixa sensibilidade e especificidade na deteção de cancro 
colorretal nos estádios iniciais da doença. 
Atualmente, entre os diversos meios de diagnóstico, a técnica mais eficiente é a 
colonoscopia, contudo apresenta baixa especificidade e sensibilidade. Estudos mais 
recentes têm apontado outros biomarcadores como forma de diagnóstico e prognóstico 
para o cancro colorretal, incluindo a septina 9. Este último é um biomarcador epigenético 
atualmente comercializado. 
Este projeto teve como objetivos realizar uma análise global do genoma em termos de 
metilação do ADN e expressão genética através de um código em R, identificar mutações 
epigenéticas que ocorram ao longo da progressão do cancro colorretal, e, por último, 
relacionar estas alterações com o efeito causado nos doentes. 
Métodos: Neste projeto, foi efetuada uma análise global do genoma de um cohort de 
cancro colorretal, em termos de metilação do ADN (Illumina Infinium 
HumanMethylation 450K array) e expressão genética (Illumina HiSeq). Neste projeto, 
foram analisadas 21 amostras de tecido normal adjacente ao tumor e 347 amostras 
tumorais divididas de acordo com a classificação TNM (54 estadio I, 131 estadio II, 111 
estadio III e 51 estadio IV). Estes dados estão publicamente disponíveis, sendo que foram 
descarregados da base de dados do The Cancer Genome Atlas (TCGA) e analisados 
através de programação em R. 
Resultados: Os resultados sugerem que nos estádios I, II, III e IV, estão diferencialmente 
expressos 307, 400, 305 e 233 genes (valor absoluto de fold-change > 1,5 e p-value 
ajustado (FDR) < 0.05) e diferencialmente metilados 924, 1.814, 1.169 e 618 locais de 
metilação (valor absoluto de Δβ > 0,2 e p-value ajustado (FDR) < 0.05), respetivamente. 
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Em adição, cada um destes locais de metilação encontra-se correlacionado com os 
respetivos genes encontrados diferencialmente expressos no mesmo estadio (p-value < 
0.05). De seguida, efetuou-se uma análise nas bases de dados KEGG e Gene Ontology 
(GO). A utilização destas ferramentas revelou que as funções mais enriquecidas estão 
relacionadas com o sistema nervoso. Estudos anteriores já tinham descrito alterações em 
genes envolvidos no desenvolvimento e regulação do sistema nervoso como desreguladas 
em diversos tipos de cancro. Em adição, foi ainda realizada uma análise com o objetivo 
de encontrar quais dos genes encontrados diferencialmente expressos e que continham 
locais de metilação diferencialmente metilados ainda não tinham sido reportados em 
associação com cancro colorretal e cancro em geral. Esta análise sugere que 87 genes 
nunca foram associados nem com cancro colorretal nem com cancro no geral. Em 
oposição, 511 já forma reportados em algum tipo de cancro. Destes últimos, 278 já foram 
também reportados em cancro colorretal enquanto 233 nunca foram descritos neste tipo 
de cancro. 
Como forma de validação, realizou-se, ainda, uma técnica multivariada de representação 
gráfica, a qual demonstrou que tanto os genes como os locais de metilação selecionados 
conseguem distinguir amostras tumorais de amostras normais. Esta técnica permitiu-nos 
ainda diferenciar amostras tumorais em dois grupos principais distintos. 
Ainda neste estudo, foram identificados 66, 85, 41 e 40 genes que estão somente 
diferencialmente expressos nos estádios I, II, III e IV. Curiosamente, apenas 85 genes são 
comuns aos 4 estadios de desenvolvimento de cancro colorretal  
O potencial dos genes e locais de metilação, encontrados como diferencialmente 
expressos e metilados, respetivamente, para distinguir tecido tumoral do tecido normal 
também foi avaliado através da análise de curvas de receiver operating characteristic 
(ROC). Como resultado, obteve-se que 238 genes e 835 locais de metilação são bons 
marcadores de tecido tumoral em estadio I, quando comparado com tecido normal 
adjacente (AUC > 0,8, sendo que apenas foram selecionados os pontos ótimos com 
especificidade e sensibilidade > 60%). ASTN1, por exemplo, foi um dos genes 
classificados como um excelente marcador de diagnóstico (AUC =0,989). Este gene 
contém ainda o local de metilação cg08104310, o qual foi considerado um excelente 
marcador de diagnóstico (AUC=1,000). 
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De seguida, a capacidade de prever o outcome do paciente em termos de sobrevida em 
geral e sobrevida livre de progressão, através dos valores de metilação e expressão dos 
genes e locais de metilação específicos para cada um dos estádios, foi avaliada. Em 
relação à sobrevivência em geral, para os estádios II, III e IV, foram identificados 6, 1 e 
5 genes e 87, 7 e 3 locais de metilação, respetivamente, como possíveis biomarcadores de 
prognóstico (p-value < 0.05). Especificamente, genes como o ZNF536 (p-value=0,018; 
HR=3,133), SOX1 (p-value=0,041; HR=0.459) e BFSP2 (p-value=0,027; HR=2.828), por 
exemplo, foram identificados como bons preditores de sobrevivência em geral dos 
estádios II, III e IV, respetivamente. Relativamente aos locais de metilação, as 
cg02430935 localizada no gene HMX (p-value=0,013; HR=3,139), cg26489108 
localizada no gene DMRT3 (p-value=0,027; HR=0,407) e a cg01847754 localizada no 
gene CXorf1 (p-value=0,019; HR=3,155), por exemplo, foram identificadas como bons 
marcadores para a sobrevivência em geral dos estádios II, III e IV, respetivamente. 
Quanto à sobrevivência livre de recorrência, para os estádios II, III e IV, foram 
identificados 3, 3 e 2 genes e 30, 12 e 9 locais de metilação, respetivamente, capazes de 
prever se o doente para recorrer ou não. Mais concretamente, genes como o CNTD2 (p-
value=0,00033; HR=0,196), SOX1 (p-value=0.01; HR=0,359) e HTR2C (p-
value=0,0064; HR=0,285) foram identificados como bons preditores de prognóstico para 
a sobrevivência livre de progressão nos estádios II, III e IV, respetivamente. 
Relativamente aos locais de metilação, as cg06162589 localizada no gene SLC5A8 (p-
value=0.0066; HR=0,2924), cg03700449 localizada no gene ASCL1 (p-value=0.0055; 
HR=0,3114) e cg14772660 localizada no gene SLC5A7 (p-value=0.0047; HR=4,3174) 
são exemplos de bons preditores de sobrevivência livre de progressão para os estádios II, 
III e IV, respetivamente.  
Conclusão: Este estudo sugere que as alterações epigenéticas são dinâmicas ao longo da 
progressão de cancro colorretal, demonstrando que há alterações que são características 
de estádios específicos, enquanto outras se mantêm alteradas desde o primeiro estadio. 
Notavelmente, algumas das alterações conseguem distinguir doentes com um prognóstico 
mais severo de doentes com um prognóstico mais indolente. 
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Assim sendo, este estudo mostrou que existem possíveis biomarcadores para cancro 
colorretal que devem ser melhor estudados no futuro. Este estudo pode ainda demarcar o 
início da melhoria das técnicas de diagnóstico e prognóstico. 
 
Palavras-chave: Cancro Colorretal, Epigenética, Metilação do ADN, Biomarcadores, 
Diagnóstico, Prognóstico.  
xv 
 
 INDEX OF CONTENTS 
 
Agradecimentos ......................................................................................................................... vii 
Abstract ....................................................................................................................................... ix 
Resumo ........................................................................................................................................ xi 
INDEX OF FIGURES ............................................................................................................. xvii 
INDEX OF TABLES .............................................................................................................. xviii 
ABBREVIATIONS LIST ........................................................................................................ xix 
1. CHAPTER I- INTRODUCTION ...................................................................................... 1 
1.1. Cancer ........................................................................................................................... 1 
1.1.1. Epidemiology of Cancer ........................................................................................ 2 
1.1.2. Mutation in Tumorigenesis ................................................................................... 2 
1.1.3. Hallmarks of Cancer .............................................................................................. 3 
1.2. Main Pathways Altered in Cancer ................................................................................. 7 
1.2.1. TGFβ Pathway....................................................................................................... 7 
1.2.2. Myc Pathway ......................................................................................................... 8 
1.2.3. PI3K Pathway ........................................................................................................ 9 
1.2.4. RTK/RAS Pathway ............................................................................................. 10 
1.2.5. NRF2 Pathway .................................................................................................... 11 
1.2.6. Wnt Pathway ....................................................................................................... 12 
1.2.7. p53 Pathway ........................................................................................................ 13 
1.2.8. Notch Pathway .................................................................................................... 14 
1.3. Colorectal Cancer ........................................................................................................ 15 
1.3.1. Epidemiology of CRC ......................................................................................... 15 
1.3.2. Disease subtypes ................................................................................................. 17 
1.3.3. Colorectal Cancer Model .................................................................................... 17 
1.3.4. Staging Systems .................................................................................................. 19 
1.3.5. Screening, Diagnosis and Prognosis ................................................................... 20 
1.4. Epigenetics .................................................................................................................. 21 
1.4.1. microRNAs.......................................................................................................... 22 
1.4.2. Histone Modifications ......................................................................................... 24 
1.4.3. DNA Methylation ................................................................................................ 26 
1.4.4. Epigenetic Alterations and Colorectal Cancer .................................................... 28 
1.4.5. Epigenetic biomarkers as predictors of clinical outcome .................................... 29 
1.5. Databases Analysis and Statistic Methodologies ........................................................ 29 
2. CHAPTER II- OBJECTIVES .......................................................................................... 32 
xvi 
 
3. CHAPTER III- MATERIALS AND METHODS .......................................................... 33 
3.1. Data Collection ............................................................................................................ 33 
3.1.1. The Cancer Genome Atlas .................................................................................. 33 
3.2. Patient Selection .......................................................................................................... 34 
3.3. Study Pipeline ............................................................................................................. 36 
3.4. Statistical Testing ........................................................................................................ 38 
3.4.1. Handling Outliers ................................................................................................ 39 
3.4.2. Shapiro-Wilk Normality Test .............................................................................. 39 
3.4.3. Paired and Unpaired Two-Sample Tests ............................................................. 40 
3.4.4. Levene Test ......................................................................................................... 41 
3.4.5. Correction for Multiple Testing .......................................................................... 42 
3.4.6. Pearson Correlation ............................................................................................. 42 
3.4.7. Receiver operating characteristic (ROC) curve analysis ..................................... 43 
3.4.8. Overall Survival and Recurrence Free Survival Analysis ................................... 44 
3.4.9. HJ-Biplot and Hierarchical Clusters .................................................................... 44 
3.5. Citation Tool ............................................................................................................... 45 
3.6. Enrichment Analysis ................................................................................................... 46 
4. CHAPTER IV- RESULTS ............................................................................................... 47 
4.1. Clinical Features .......................................................................................................... 47 
4.2. Epigenetic Roadmap in Colorectal Cancer ................................................................. 48 
4.3. Nervous System Related Functions are Enriched in CRC .......................................... 53 
4.4. Identification of potential New Biomarkers for CRC ................................................. 55 
4.5. Identification of genes epigenetically regulated which characterize CRC progression
 56 
4.6. Potential New Biomarkers for Colorectal Cancer Diagnosis ...................................... 60 
4.7. Identification of Epigenetic Biomarkers which predict patient outcome .................... 62 
4.8. CRC patients can be grouped according to their gene expression and DNA 
methylation patterns ................................................................................................................ 69 
5. CHAPTER V- DISCUSSION ........................................................................................... 74 
5.1. Limitations .................................................................................................................. 82 
6. CHAPTER VI- CONCLUSION ...................................................................................... 83 
REFERENCES .......................................................................................................................... 85 
 
  
xvii 
 
INDEX OF FIGURES 
Figure 1.1 Hallmarks of cancer new capabilities of tumor cells acquired during tumorigenesis . 7 
Figure 1.2 Schematic figure representing TGFβ signaling .......................................................... 8 
Figure 1.3 Schematic figure representing the Myc pathway ........................................................ 9 
Figure 1.4 Schematic figure representing PI3K pathway. .......................................................... 10 
Figure 1.5 Schematic figure representing Ras activation ........................................................... 11 
Figure 1.6 Schematic figure representing NRF2 pathway ......................................................... 12 
Figure 1.7 Schematic figure representing Wnt pathway ............................................................ 13 
Figure 1.8 Schematic figure representing p53 pathway ............................................................. 14 
Figure 1.9 Schematic figure representing Notch pathway ......................................................... 15 
Figure 1.10 Cancer incidence and mortality in Portugal, 2012 .................................................. 16 
Figure 1.11 A heterogenous tumor. ............................................................................................ 18 
Figure 1.12 Adenoma–carcinoma sequence model .................................................................... 19 
Figure 1.13 Schematic representation of epigenetic modifications ............................................ 22 
Figure 1.14 miRNA processing .................................................................................................. 24 
Figure 1.15 Nucleosome assembly and post-translational modification of histone tails ........... 25 
Figure 1.16 Hypermethylation can lead to gene inactivation ..................................................... 27 
Figure 1.17 Promoter hypermethylation can be associated with gene activation....................... 28 
Figure 1.18 The amount of data available contributes to the biology research .......................... 31 
Figure 3.1 TCGA by numbers. ................................................................................................... 33 
Figure 3.2 Sample selection using R programming ................................................................... 35 
Figure 3.3 The approach to remove duplicated cases ................................................................. 36 
Figure 3.4 Study Pipeline ........................................................................................................... 37 
Figure 3.5 Function to remove outliers ...................................................................................... 39 
Figure 3.6 Adapted functions to compare two-samples ............................................................. 41 
Figure 3.7 Adapted function to perform the Levene test. ........................................................... 41 
Figure 3.8 Functions to obtain the number of citations in PubMed for each gene ..................... 46 
Figure 4.1 Study pipeline indicating CpG sites and genes selected for each stage .................... 49 
Figure 4.2 Characterization of CpG sites differentially methylated throughout CRC development
 ............................................................................................................................................. 51 
Figure 4.3 Localization of CpG sites differentially methylated in the gene ............................... 52 
Figure 4.4 Enriched pathways across colorectal cancer development ....................................... 54 
Figure 4.5 Enriched biological process: gene ontology (GO). ................................................... 55 
Figure 4.6 Potential new epigenetic biomarkers for colorectal cancer ....................................... 56 
Figure 4.7 Genes epigenetically regulated across colorectal cancer development ..................... 57 
Figure 4.8 Epigenetic dynamic in CRC ...................................................................................... 58 
Figure 4.9 CpG sites differentially methylated across colorectal cancer development. ............. 60 
Figure 4.10 ASTN1 gene has the potential to distinguish stage I colorectal tumor tissue from 
normal tissue ....................................................................................................................... 62 
Figure 4.11 Epigenetically altered genes can predict patient outcome ...................................... 64 
Figure 4.12 CpG sites predict patient outcome .......................................................................... 65 
Figure 4.13 Recurrence Free Survival prediction through gene expression levels .................... 67 
Figure 4.14 CpG sites can predict recurrence ............................................................................ 69 
Figure 4.15 HJ-biplot representation of gene expression for (A) stage I, (B) stage II, (C) stage III, 
and (D) stage IV of CRC ..................................................................................................... 71 
Figure 4.16 HJ biplot representation of DNA methylation for (A) stage I, (B) stage II, (C) stage 
III, and (D) stage IV ............................................................................................................ 73 
 
xviii 
 
INDEX OF TABLES 
Table 1.1 Colorectal Cancer staging according to the most recent AJCC system effective on 
January 2018 ....................................................................................................................... 20 
Table 3.1 Correlation coefficient interpretation.. ....................................................................... 42 
Table 3.2 Classification of the diagnostic accuracy. .................................................................. 43 
Table 4.1 Descriptive statistics about patients, as well as the distribution of patients by stage. 48 
Table 4.2 The top 15 most differentially expressed genes for each stage of disease ................. 53 
Table 4.3 Top 10 specific CpG sites most differentially methylated in each stage. ................... 59 
Table 4.4 Genes that better predict the outcome (overall survival) ............................................ 63 
Table 4.5 Genes that better predict the outcome (recurrence free survival) ............................... 66 
  
xix 
 
ABBREVIATIONS LIST 
3’ UTR- Three Prime Untranslated Region 
5’ UTR- Five Prime Untranslated Region 
ALS- Amyotrophic Lateral Sclerosis 
APC- Adenomatous Polyposis Coli 
ATP- Adenosine Triphosphate 
AUC- Area Under the Curve 
BAX- BCL2 Associated X 
BRAF- B-Raf Proto-Oncogene 
CA- Cancer Antigen  
CDC4- Cell Division Cycle 4 
CEA- CarcinoEmbryonic Antigen 
CIMP- CpG Island Methylator Phenotype 
CIN- Chromosome Instability 
CpG- Cytosine phosphate Guanine 
CRC- Colorectal cancer 
DNA- Deoxyribonucleic acid 
DNMT- DNA methyltransferase 
EGFR- EGF receptor 
FDR- False Discovery Rate 
FIT- Fecal Immunochemical Test 
FOBT- Fecal Occult Blood Testing 
FPF- False positive fraction 
FS- Flexible Sigmoidoscopy 
xx 
 
GO- Gene Ontology 
H3K27ac- Acetylation of histone 3 at lysine 27 
H3K27me3- Tri methylation of histone 3 at lysine 27 
H3K36me3- Tri methylation of histone 3 at lysine 36 
H3K4me1- Mono methylation of histone 3 at lysine 4 
H3K4me3- Tri methylation of histone 3 at lysine 4 
H3K9me3- Tri methylation of histone 3 at lysine 9 
HAT- Histone acetyltransferases 
HDAC- Histone deacetylases 
HDM- Histone demethylases 
HMT- Histone methyltransferases 
HR- Hazard ratio 
ID4- Inhibitor of DNA Binding 4 
IGF2R- Insulin-like Growth Factor 2 Receptor 
Indel- Insertion and Deletion 
IRF8- Interferon Regulatory Factor 8 
ITGA4- Integrin Subunit Alpha 4 
KM- Kaplan-Meier 
Last1- Large Tumor Suppressor 1 
Last2- Large Tumor Suppressor 2 
MBD- Methyl-CpG-binding domain 
MGMT- O-6-Methylguanine-DNA Methyltransferase 
MiRNA- MicroRNA 
xxi 
 
MLH1- MutL Homolog 1 
mRNA- Messenger RNA 
MSH3- MutS Homolog 3 
MSH6- MutS Homolog 6 
MSI- Microsatellite instability 
Mst1- Mammalian STE20-like Protein Kinase 1 
Mst2- Mammalian STE20-like Protein Kinase 2 
NCI- National Cancer Institute 
NHGRI- National Human Genome Research Institute 
NIH- National Institute of Health 
PCA- Principal Component Analysis 
PIP2- phosphatidylinositol (4,5)-bisphosphate 
PIP3- phosphatidylinositol (3,4,5)-triphosphate 
Pol II- Polymerase II 
Pre-miRNA- Precursor miRNA 
Pri-miRNA- Primary microRNA 
PTEN- Phosphatase and Tensin Homolog 
Rb- Retinoblastoma 
RISC- RNA-induced silencing complex 
RNA- Ribonucleic acid 
RNase- Ribonuclease 
ROC - Receiver operating characteristic 
RTKs- Receptor tyrosine kinases 
xxii 
 
SDC2- Syndecan 2 
SEPT9- Septin 9 
SFRP2- Secreted Frizzled Related Protein 2 
SLC5A8- Solute Carrier Family 5 Member 8 
TAZ- Transcriptional Co-Activator with PDZ-Binding Motif 
TCGA- The Cancer Genome Atlas 
TEAD- Transcriptional Enhanced Associate Domain  
TEAP2E- Transcription factor AP-2 epsilon 
TGFBR2- TGFβ receptor 2 
THBD- Thrombomodulin 
TIMP3- TIMP Metallopeptidase Inhibitor 3 
TP53- Tumor Protein 53 
TPF- True positive fraction 
TSP-1- Thrombospondin-1 
TSS- Transcription Start Site 
VEGF-A- Vascular Endothelial Growth Factor-A 
VIM- Vimentin 
YAP- Yes-associated Protein 
  
1 
 
1. CHAPTER I- INTRODUCTION 
 
 
1.1. Cancer 
Historically, the humoral theory, proposed by Hippocrates, was the first trying to explain 
what cancer is. He believed that humans contained 4 body fluids, named humor fluids: 
blood, phlegm, yellow bile, and black bile, which could be the cause of cancer. 
Specifically, Hippocrates proposed that alterations on these substances including an 
abnormal increase of black bile led cancer to arise1. 
It was only in 1838 that it was demonstrated that cancer is formed by cells which are 
derived from other cells- the blastema theory23. After, other theories arose, including the 
chronic irritation theory, which suggested that cancer was caused by chronic irritation; 
the trauma theory, which asserted that trauma led to cancer, and the parasite theory, which 
characterized cancer as a contagious disease that could be transmitted among humans 
through parasites2,4,5. 
Despite multiple attempts to understand the cause of cancer, it was in the 20th century that 
the mystery started to be solved. Firstly, both Watson and Crick uncovered the structure 
of deoxyribonucleic acid (DNA). Then, it was revealed how genes work and that genes 
can be affected by mutations. Later, it was also discovered that DNA can be altered and 
cause cancer through the exposure to chemicals, radiation, viruses and other carcinogens. 
It was also in the same century, that oncogenes and tumor suppressor genes were 
identified2. 
Nowadays, it is known that cancer is a group of diseases characterized by uncontrolled 
cell division that ultimately can spread to other tissues and metastasize. Although 
proliferation and cellular growth being normal and essential processes for development 
of organisms, cell division can become out of control, resulting in the accumulation of 
both mutations and epimutations6. This condition may lead to an uncontrolled cellular 
growth and, ultimately, in the invasion of distant tissues7. 
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1.1.1. Epidemiology of Cancer  
Despite the significant improvement in treatment and screening and the search for tumor 
biomarkers, cancer is the second leading cause of death in the world with more than 14 
million new cancer cases reported and 8.2 million deaths worldwide in 2012. In 2018 it 
was estimated about 18.1 million new cases and 9.6 million cancer-related deaths. 
Additionally, assenting in statistical predictions, it is expected that over 23 million new 
cancer cases are diagnosed and 14 million deaths by cancer are reported in 2035. 
Among all cancer types, the most frequents are lung, breast, colorectal and prostate 
cancers8–10. 
 
1.1.2. Mutation in Tumorigenesis 
Mutations and epimutations might have an impact in gene expression by modifying DNA 
sequence or chromatin structure, respectively11. Those changes can occur under many 
circumstances such as exposure to tobacco, chemicals, radiation or infectious organisms- 
external factors- and inherited mutations, hormones, immune conditions  and random 
mutations- internal factors6. Additionally, other events can also arise during cancer 
development, such as genomic rearrangements, amplification, insertion and deletion 
(indel)12,13. 
Importantly, neither the total number of mutations nor epimutations are directly related 
to the outcome. These events can be assembled in two main groups: driver and passenger 
mutations. Driver mutations provide selective advantage to tumor cell growth, 
contributing to the tumor initiation and progression. In contrast, passenger mutations do 
not provide selective growth advantage, meaning that they do not contribute to tumor 
initiation and progression. Driver mutations happen in small scale in cancer, whereas 
passenger mutations are the most common alterations found in cancer cells. Additionally, 
there is another type of mutations, named gatekeeping mutations, which provide 
advantages to the growth of normal cells13–17. 
Among all cellular processes, cell fate determination, cell survival, and genome 
maintenance are the three main processes related to cancer driver genes13. These 
processes are regulated by several oncogenes and tumor suppressor genes, which are often 
activated or inactivated, respectively, across the tumor development16. 
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1.1.3. Hallmarks of Cancer 
Hanahan and Weinberg have originally proposed six hallmarks that normal cells acquire 
during the malignant transformation, which promote tumor growth and progression, 
revolutionizing the knowledge of tumorigenesis (Figure 1.1)18,19: 
 
a. Sustaining proliferative signaling. 
Cancer cells can affect the production and release of growth-promoting signals, such as 
growth factors that bind to cell-surface receptors. This control affects the cell cycle and 
cell growth, leading to an uncontrolled proliferation. Specifically, there are different 
known ways to take control of proliferation such as an autocrine proliferative stimulation, 
meaning that cancer cells produce growth factors themselves; or stimulating normal cells 
to produce growth factors. Moreover, mechanisms as somatic mutations that activate 
additional downstream pathways, or the disruption of negative feedback mechanisms that 
inhibits proliferative signaling are also commonly observed18–21. 
 
b. Evading growth suppressors. 
Besides cancer cells constitutively activate proliferative signals, they inhibit growth 
suppressors (tumor suppressor genes). Among all known tumor suppressor genes, the 
most studied are Retinoblastoma (Rb) and Tumor Protein 53 (TP53). Both are involved 
in the control of cell cycle, being responsible to decide if the cell proliferates or enters in 
senesce or apoptosis. Moreover, the cell-cell contact is also lost in several types of cancer, 
in order to maintain the uncontrolled cell growth18,19,22,23. Indeed, this fact contributes to 
cancer development and metastization as well24. 
 
c. Resisting cell death. 
Cancer cells avoid apoptosis, a programed mechanism of cellular death. Indeed, there are 
regulators that receive and process the extracellular death-inducing signals, as well as 
regulators that sense and integrate signals of intracellular origin. As a consequence of the 
activation of any of these regulators, the apoptotic effectors are also activated and the cell 
suffers apoptosis, being digested by both its neighbors and phagocytic cells25. In cancer, 
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this mechanism is abnormally altered, leading to the proliferation of damaged cells. For 
example, cancer cells lose the tumor suppressor gene TP53, which is responsible for 
inducing apoptosis. Other strategies, such as to increased expression (upregulation) of 
antiapoptotic regulators and survival signals, or to downregulate proapoptotic factors are 
also commonly observed in several types of cancer as a way to avoid apoptosis18,19,26,27. 
 
d. Enabling replicative immortality. 
Although normal cells have a limited number of cell divisions, cancer cells acquire the 
capability of dividing indefinitely. Specifically, cancer cells evade both senescence and 
crisis/apoptosis, being able to proliferate indeterminately. There are evidences that this 
feature is, in part, due to the activation of telomerase, a DNA polymerase that is 
responsible by the maintenance of the repetitive sequences located at the ends of 
chromosomes, named telomeres, which ultimately leads to cell immortalization. 
Remarkably, studies demonstrated that most non-immortalized cells do not express the 
gene that encodes for telomerase whereas about 90% of spontaneous immortalized cells 
do. Moreover, there are evidences that this alteration is correlated to resistance to 
senescence and crisis/apoptosis, and is associated to poor prognosis18,19,28,29. 
 
e. Inducing angiogenesis. 
During malignant transformation, cancer cells are able to induce angiogenesis with the 
purpose of obtaining nutrients and oxygen as well as remove metabolic wastes and carbon 
dioxide. This process is mediated by vascular endothelial growth factor-A (VEGF-A), a 
promotor of angiogenesis, and thrombospondin-1 (TSP-1), an inhibitor of angiogenesis. 
Moreover, the production of new blood vessels due to a chronic activation of angiogenesis 
has liabilities, resulting in precocious capillary sprouting, convoluted and excessive 
vessel branching, distorted and enlarged vessels, erratic blood flow, micro hemorrhaging, 
leakiness, and abnormal levels of endothelial cell proliferation and apoptosis. 
Studies have revealed that angiogenesis is important in microscopic premalignant stages 
as well as in later cancer stages as it promotes tumor mass growth18,19,30,31. 
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f. Activating invasion and metastasis. 
In advanced stages of the disease, a tumor mass with epithelial origin can spread to other 
tissues through the epithelial-mesenchymal transition mechanism. During this process, 
cancer cells must be altered in order to efficiently invade and metastasize. This process is 
characterized by shape alterations, as well as the loss of adhesion properties to 
neighboring cells and to the extracellular matrix. In detail, loss of proteins such as E-
cadherin, cytokeratin, or laminin-1, involved in the cell adhesion, is often observed in 
tumors of epithelial origin. Additionally, studies have also demonstrated alteration of 
these class of proteins in other types of cancer, including breast cancer32, lung cancer33, 
and colorectal cancer34. Not only that, molecules associated to cell migration during 
embryogenesis and the inflammation processes were found deregulated18,19,35,36. 
More recently, four additional tumor characteristics were added to the “hallmarks of 
cancer”: genome instability and mutation, tumor-promoting inflammation, deregulating 
cellular energetics and avoiding immune destruction (Figure 1.1)19. 
 
g. Genome instability and mutation 
Throughout tumorigenesis, cancer cells acquire mutations and genomic instability, due to 
aberrant alterations in multiple genes including oncogenes and tumor suppressor genes. 
In this sense, cancer cell ability to detect and resolve DNA errors is reduced, and therefore 
there is increased mutation burden. Thus, cancer cells can acquire alterations that confer 
selective advantage, promoting cancer progression. Remarkably, these alterations are 
transmitted to daughter-cells during the cell cycle, leading to a mass constituted by clones 
of those cells. Moreover, there are evidences that genes involved in the detection and 
repair of DNA damage, or cell growth and proliferation, as TP53, ATM, and BRCA1 are 
frequently altered in order to promote tumorigenesis17,19,37–39. 
 
h. Tumor-promoting inflammation 
Tumor-promoting inflammation is also considered a cancer characteristic, since it has 
been found infiltrated innate and adaptative immune cells in tumors. Specifically, 
inflammatory cells, which are present in the tumor microenvironment, play a key role in 
tumor progression by facilitating the availability of molecules that promote 
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tumorigenesis, such as growth factors, survival factors, proangiogenic factors, 
extracellular matrix-modifying enzymes, and inductive signals to induce invasion and 
metastasis. Importantly, those inflammatory cells can also release chemicals that act as 
mutagenic factors to cancer cells, promoting cancer development19,40,41. 
 
i. Deregulating cellular energetics 
Cancer cells need to change their metabolic program in order to facilitate cancer 
progression. Therefore, in both absence and presence of oxygen, cancer cells metabolize 
glucose through anaerobic glycolysis, a process commonly used by normal cells only in 
the absence of oxygen. Although, glycolysis is a faster process when compared to 
mitochondrial phosphorylation, it is a less efficient way of adenosine triphosphate (ATP) 
production. Thus, in a process of aerobic glycolysis, cancer cells increase glucose 
transporters (GLUTs) as well as the uptake and utilization of glucose. Additionally, 
glycolysis is associated with cell proliferation, due to the facilitation of macromolecules 
and organelles biosynthesis achieved from glycolytic intermediates19,42,43. 
 
j. Avoiding immune destruction 
Although avoiding immune destruction is an emerging hallmark of cancer, this process is 
yet to be fully understood. The immune system cannot eliminate cancer cells neither in 
early/later stages nor in micro metastases. Studies have suggested that in order for cancer 
cells to escape from immune destruction, they block the function of components from the 
immune system as well as secretions that can eliminate them. For example, cancer cells 
alter their cell surface antigens in order to avoid recognition by the immune system cells. 
In this sense, cancer cells develop strategies to evade immune destruction, leading to the 
down-regulation of the immune system and consequently increasing cancer cells 
proliferation19,44. 
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1.2. Main Pathways Altered in Cancer 
For the past years, several pathways have been reported to be aberrantly regulated during 
cancer development and progression, including the following45: 
 
1.2.1. TGFβ Pathway 
TGFβ pathway is frequently affected in cancer, since it regulates processes such as cell 
proliferation, apoptosis, and immortalization which are often altered in this disease. When 
TGFβ activates its receptor (TGFβ receptor), both Smad2 and Smad3 are phosphorylated. 
and associated with Smad4, constituting a complex that migrates to the nucleus. As a 
result, proteins that inhibit the cell cycle, as Smad7 and Skil, are produced, leading to cell 
cycle blockade (Figure 1.2)46–48. 
In cancer, mutations/deletions in Smad2, can inactivate the TGFβ pathway, leading to cell 
cycle progression even in the presence of cell damage7,49. Moreover, the TGFβ receptor 
can also loose it functions due to mutations or DNA methylation of its promoter, leading 
to inactivation of the pathway. 
Figure 1.1 Hallmarks of cancer. Capabilities of tumor cells acquired during tumorigenesis (adapted 
from Hanahan and Weinberg, 2011). 
8 
 
However, several studies have also demonstrated that TGFβ can be up-regulated in 
metastatic cancer cells when compared to normal cells. Specifically, TGFβ can induce 
the remodulation of the extracellular matrix, leading to immunosuppression, angiogenesis 
and activation of myofibroblast differentiation50–52. 
 
 
1.2.2. Myc Pathway 
Myc is considered to have oncogenic properties due to its ability to promote cell cycle 
progression. In fact, in order for the cell to divide it needs to fulfill multiple requisites 
which are verified in a checkpoint (R point). If all is correct, Myc forms a heterodimer 
with Max, inducing the expression of proteins that promote the cell cycle. 
Simultaneously, Myc can initiate the S phase through the activation of transcription 
factors. To note there are other pathways that can trigger Myc activation, such as Wnt, 
Notch, which are approached below. Contrarily, TGFβ signaling can block it (Figure 
1.3). 
Figure 1.2 Schematic figure representing TGFβ signaling pathway. The activation of TGFβ 
receptor induces proteins that inhibits cell cycle progression (from Tecalco-Cruz et al. 2018). 
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Hence, genetic or epigenetic alterations that induce aberrant expression of Myc in cancer 
promotes cell growth and proliferation7,53,54. 
 
 
1.2.3. PI3K Pathway 
PI3K is an intracellular lipid kinase that, when activated, leads to the conversion of 
phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-
triphosphate (PIP3), by phosphorylate PIP2. As a result, cytoplasmic proteins, including 
AKT, can bind to PIP3. Then, two kinases, PDK1 and PDK2, phosphorylate AKT in two 
sites, leading to its activation. Consequently, AKT kinase phosphorylates other substrates 
that regulate cell proliferation, survival, and size. Recently, there are evidences that 
PDK1, when activated, can also induce the expression of Myc through phosphorylation 
of PLK1. Moreover, PTEN can dephosphorylate PIP3, converting it to PIP2, leading to 
the block of the activity of AKT (Figure 1.4)7,55–57. 
Since PI3K signaling regulates several mechanisms, including cell motility, growth, 
proliferation, and metabolism, it can play a key role in carcinogenesis. Therefore, this 
pathway is commonly activated in cancer through several mechanisms, including 
Figure 1.3 Schematic figure representing the Myc pathway. Myc protein can induce processes 
as ribosome biogenesis, glycolysis, and DNA replication cell cycle (adapted from Dang 2010). 
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genomic alterations involving PIK3CA, PIK3R1, PTEN, AKT, TSC1, MTOR, and TSC2, 
58. 
 
 
1.2.4. RTK/RAS Pathway 
Receptor tyrosine kinases (RTKs) are receptors located in the cell surface and constituted 
by an extracellular (N-terminal), a transmembrane and a cytoplasmic kinase domain. This 
type of receptors, when activated by growth factors, hormones, cytokines, neurotrophic 
factors and other extracellular signaling molecules, stimulate cell proliferation, 
differentiation, survival and cell migration. 
RTKs are monomers, which, when activated by an extracellular stimulus of its N-terminal 
region, forms a dimer. This dimerization leads to the auto phosphorylation of the receptor, 
creating a dock site to a complex that can activate Ras, a GTPase protein, that hydrolysis 
GTP into GDP. Consequently, when the RTK is phosphorylated, Ras is activated, 
inducing pathways as MAPK and PI3K. Thus, genes involved in cell proliferation and 
survival are activated (Figure 1.5)59,60. 
Figure 1.4 Schematic figure representing the PI3K pathway. PI3K converts PIP2 into PIP3, 
leading to the activation of AKT and Myc. As a result, genes involved in cell proliferation and 
survival are activated (from Cunningham et al. 2013). 
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In cancer, Ras is found frequently mutated, leading to its constitutive activation. Once, 
permanently activated Ras is incapable of releasing GTP, and therefore the hydrolysis of 
GTP into GDP is blocked, leading to a constitutive activation of downstream signaling7. 
 
1.2.5. NRF2 Pathway 
Generally, the transcription factor Nrf2 is considered a tumor suppressor gene, since its 
activation leads to the stimulation of genes involved in the defense of the cell against 
metabolic, xenobiotic, and oxidative stress. In fact, when the cell experiences endogenous 
or exogenous stress, there is an increase in Nrf2 levels, due to the non-ubiquitination of 
it by KEAP1. Thus, Nrf2 is translocated to the nucleus where it forms a heterodimer with 
MAF and binds to the antioxidant response element (Figure 1.6). As a result, genes 
involved in metabolism, intracellular redox-balancing, apoptosis, and autophagy are 
transcribed61–63. 
Figure 1.5 Schematic figure representing Ras activation. The phosphorylation of RTK leads 
to the activation of Ras (adapted from Schöneborn et al. 2018) 
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Also, it is believed that Nrf2 can also act as an oncogene, by promoting the survival of 
cancer cells. Specifically, studies suggested that due to the anti-oxidant effect of Nrf2, 
cancer cells can be protected from excessive oxidative stress, chemotherapeutic agents, 
or radiotherapy. However, this oncogenic role in carcinogenesis is yet to be fully 
understood61–63. 
 
1.2.6. Wnt Pathway 
When the Wnt protein binds to its receptor it leads to the inactivation of glycogen synthase 
kinase-3β (GSK-3β) preventing the phosphorylation of β-catenin and blocking its 
degradation. Therefore, β-catenin migrates to the nucleus, where it associates with 
transcription factors leading to the expression of genes involved in cell proliferation 
(Figure 1.7). 
In cancer, the aberrant activation of Wnt pathway can lead to increased translocation of 
β-catenin into the nucleus, and, consequently, promote the transcription of genes that 
promote cell survival and proliferation. Moreover, alterations of Apc, a protein that 
Figure 1.6 Schematic figure representing NRF2 pathway. NRF2 pathway induces the 
transcription of genes involved in the protection of oxidative stress (adapted from Zhao et al. 
2017). 
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participates in the complex that promotes the degradation of β-catenin, are also frequent 
in cancer7,64,65. 
 
 
 
1.2.7. p53 Pathway 
p53, considered the master guardian of the genome, plays a key role in apoptosis control, 
cell cycle arrest and DNA damaged repair (Figure 1.8). Cell stress events, including DNA 
damage, oncogenic stress, hypoxia, and telomerase erosion, activate the p53 pathway. 
Specifically, the kinase ATM can block Mdm2, a p53 inhibitor, by phosphorylate it. This 
event leads to p53 activation, which in turn induces the expression of genes that block 
cell division and DNA repair, or trigger programmed cell death (Figure 1.8)66–69. 
Figure 1.7 Schematic figure representing the Wnt pathway. The expression of Wnt protein 
blocks the degradation of β-catenin, leading to the transcription of genes involved in cell 
proliferation (from Centelles 2012). 
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In cancer, levels of p53 can be reduced, or the protein can be sequestered in the nucleus, 
inactivating its function7. Furthermore, mutations in TP53 can affect its folding resulting 
in the proliferation of cells with DNA damage and therefore promoting cancer69. 
 
1.2.8. Notch Pathway 
When the Notch receptor is activated by its Delta or Jagged ligands, suffers a proteolytic 
cut. As a consequence, a cytoplasmatic fragment is translocated into the nucleus, where 
it activates the expression of genes involved in cell proliferation, by participating in a 
transcription factor complex (Figure 1.9). 
In cancer, there are reports that an increased expression or truncated forms of the Notch 
receptor are common ways to induce cell proliferation. Moreover, an increased 
expression of Notch ligands is also observed in several types of cancer. Also constitutive 
expression of Notch, due to deletions in the gene that encodes the extracellular domain of 
the protein, is also reported in cancer7,70–72. 
 
Figure 1.8 Schematic figure representing p53 pathway. When p53 is activated, genes 
responsible by apoptosis, cell cycle arrest and DNA repair are transcribed (adapted from Boland 
et al. 2005). 
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1.3. Colorectal Cancer 
Colorectal cancer (CRC) consists in a multistep process which occurs due to both genetic 
and epigenetic alteration leading to silencing of tumor suppressors genes and increased 
expression of oncogenes, ultimately promoting cellular growth73. This process evolves 
from a hyperplasia into a adenocarcinoma which ultimately becomes able to metastasize 
to organs such as liver, lung, peritoneum, bone or brain74. 
 
1.3.1. Epidemiology of CRC 
According to statistical data available in GLOBOCAN about the year 2012, CRC is the 
third most common cancer in men and the second in women with 1, 3 million new cases 
diagnosed, and 693,933 deaths in the world. In Portugal, during 2012, 7,129 new cases 
of CRC, and 3,797 deaths due to this disease were reported (Figure 1.10). 
Figure 1.9 Schematic figure representing the Notch pathway. The expression of Notch ligands 
leads to the translocation of a cytoplasmatic fragment of Notch receptor. As a result, genes 
involved in cell proliferation are transcbribed (adapted from Avila et al. 2013). 
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The incidence is higher after 50 years of age, being the median age of diagnosis around 
70 years8,75,76. In developed regions as Australia/New Zealand, Europe and Northern 
America the incidence of CRC is higher due to risk factors as diet and lifestyle77. In 
contrast, Western Africa, Middle Africa and South-Central Asia are the regions where 
incidence rates are lower. Despite of this, mortality rates are higher in less developed 
regions due to a lack of healthcare resources. With regard to 5-year survival rates, these 
can vary greatly, ranging from around 90% in early stages of the disease to less than 10% 
when the disease has metastasized78. 
Sporadic CRC is the most frequent form of CRC representing about 75% of all CRC 
cases79. Many risk factors may contribute to cancer initiation and progression including 
family history80, age81, smoking habits82, alcohol83, and diet, including both red and 
processed meat84,85.  
 
Figure 1.10 Cancer incidence and mortality in Portugal, 2012. Colorectal Cancer is the 
most common cancer in Portugal, representing 14.5% of all cancer cases, accounting with 7129 
new cases in 2012. Moreover, Colorectal Cancer is also the deadliest cancer, being associated 
to over 15% of mortality by cancer (data source: GLOBOCAN) 
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1.3.2. Disease subtypes 
CRC can arise sporadically or affect patients who have a genetic predisposition, with 
family history, including genetic syndromes as Lynch Syndrome and familial 
adenomatous polyposis. Several genes altered in familial CRC have been identified, 
including DNA mismatch repair genes, the Adenomatous Polyposis Coli (APC), MutL 
Homolog 1 (MLH1), and Phosphatase and Tensin Homolog (PTEN)86. 
Sporadic CRC are divided into three main subtypes, depending on the molecular 
alteration in its origin: microsatellite instability (MSI), chromosomal instability (CIN), 
and CpG island methylator phenotype (CIMP). However, the tumor can be characterized 
by features of these different subtypes86. 
 
1.3.3. Colorectal Cancer Model 
The model for colon and rectum tumorigenesis was initially suggested by Fearon and 
Vogelstein. According to that model, CRC is a multistep process that arises from benign 
lesions into a malignant tumor. Across the malignant transformation, somatic alterations 
occur, including alterations in oncogenes and tumor suppressor genes87. 
It is believed that those alterations are generated and propagated through clonal evolution, 
meaning that mutations/epimutations occur in a cell, and are inherited by daughter cells 
during mitosis. When the mutations are acquired, the cell has two ways to go: either 
undergo senescence before entering in the cell cycle or avoid apoptosis and to entry in 
cell cycle. In the second case, that cell might accumulate mutations and epimutations, 
originating clones which altogether can be able to cause a heterogeneous tumor mass 
(Figure 1.11)17,88,89. 
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In CRC (Figure 1.12), chromosomal instability drives tumorigenesis, initiated by the 
inactivation of APC gene, and followed by mutations in KRAS. The increasing 
chromosomal instability leads to other successive alterations, including loss of 
heterozygosity (loss of 18q-long arm) and mutations of SMAD4, and Cell Division Cycle 
4 (CDC4). Ultimately, mutations in TP53 allow the transition from late adenomas to 
cancer90. 
Another less common way to develop CRC is through microsatellite instability which can 
facilitate tumor initiation and progression, due to lacking mismatch repair mechanisms. 
This pathway is often initiated by abnormal alterations in the Wnt signaling and followed 
by activating mutations in B-Raf Proto Oncogene (BRAF) and KRAS genes. Importantly, 
the inefficiency of mismatch repair genes, caused due to hypermethylation of MLH1 
promoter, is increased throughout tumorigenesis. Therefore, tumor cells with mutations 
in genes as MutS Homolog 3 (MSH3), MutS Homolog 6 (MSH6), TGFβ receptor 2 
(TGFBR2), Insulin-like Growth Factor 2 Receptor (IGF2R), and BCL2 Associated X 
(BAX) are positively selected. Altogether, these events lead to the activation of a 
mechanism responsible for tumor progression independent of TP5391. 
Figure 1.11 A heterogenous tumor. The accumulation of mutations and epimutations leads to a 
heterogeneous tumor mass (from Easwaran et al. 2014). 
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1.3.4. Staging Systems 
CRC can be classified according to molecular and histological features- histological 
staging- or physical exams, biopsies, and imaging tests- clinical staging. These 
classifications allow to differentiate the state of cancer evolution and decide the best 
treatment option to the patient. 
The most common method of classification used is the TNM system (Table 1.1) which 
distinguishes the cancer stages based on: 
a. Tumor size (T): size of primary tumor (range from T0-T4), 
b. Lymph nodes (N): whether cancer has spread to lymph nodes (range from N0-
N3), 
c. Metastasis (M): whether cancer has metastasized (M0 or M1). 
Higher numbers of T, N, and M are associated to most advanced disease, and, 
consequently, to worst prognosis92. Importantly, when the category cannot be determined, 
it is classified by X (TX or NX). 
The overall stage is obtained by the combination of these three characteristics93. 
 
 
Figure 1.12 Adenoma–carcinoma sequence model schematic representation of genomic 
events that occur in colon and rectum tumorigenesis (from Walther et al. 2009) 
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Table 1.1 Colorectal Cancer staging according to the most recent AJCC system effective on 
January 2018 (adapted from American Cancer Society®) 
 
 
1.3.5. Screening, Diagnosis and Prognosis 
The detection of CRC in early stages of the disease- screening- is based on colonoscopy, 
flexible sigmoidoscopy (FS), fecal occult blood testing (FOBT), and fecal 
immunochemical test (FIT). 
Currently, colonoscopy remains the most accurate test for CRC screening and diagnosis. 
This technique can detect 88-98% of advanced neoplasia. Importantly, several studies 
have reported a decrease in mortality due to colonoscopy94. FS is also used to diagnose 
CRC, with a sensitivity of 90% to detect advanced neoplasia. However, both colonoscopy 
and FS are invasive and expensive techniques. 
Overall Stage  T N M 
Stage I 
 T1 N0 M0 
 T2 N0 M0 
     
Stage IIA  T3 N0 M0 
     
Stage IIB  T4a N0 M0 
     
Stage IIC  T4b N0 M0 
     
Stage IIIA 
 T1-T2 N1/N1c M0 
 T1 N2a M0 
Stage IIIB 
    
 T3-T4a N1/N1c M0 
 T2-T3 N2a M0 
 T1-T2 N2b M0 
     
Stage IIIC  T4a N2a M0 
  T3-T4a N2b M0 
  T4b N1-N2 M0 
     
Stage IVA  Any T Any N M1a 
     
Stage IVB  Any T Any N M1b 
     
Stage IVC  Any T Any N M1c 
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As an alternative to colonoscopy, FOBT and FIT can also be used to screen CRC at lower 
costs and in a simpler way. Nevertheless, these tests exhibit low sensitivities and 
specificities. FOBT only detects 13-50% of CRC cases, and 9-24% of advanced 
neoplasia. On the other hand, the sensitivity of FIT to detect CRC, and advanced neoplasia 
is 79%, and 32-53%, respectively81,95–97. 
To predict CRC outcome, blood tests targeting tumor markers might be performed. 
Common CRC marker are the carcinoembryonic antigen (CEA), and cancer antigen 19-
9 (CA 19-9). These markers have poor sensitivity and specificity in early stages of the 
disease. Nonetheless, over the disease progression, both specificity and sensitivity 
increase98,99. 
The success of treatment and survival depends on the efficiency of screening/detection of 
cancer. In case of local CRC, the success rate is 70-90% however, in advanced CRC, the 
mortality is high88. In fact, the statistics presented by National Cancer Institute indicate 
that 92% of stage I, 63-87% stage II, 53-89% stage III, and 11% stage IV colon cancer 
patients survive at least 5 years. Similarly, the rectum cancer patients in stage I-IV have 
a 5-years survival rate about 87%, 49-80%, 58-84%, and 12%, respectively100. 
 
1.4. Epigenetics 
Epigenetics, firstly introduced by Conrad Waddington in 1940s, is defined by reversible 
alterations that affect gene expression without altering DNA sequence88,101–103. 
Regulation of gene expression mediated by epigenetic alterations, including DNA 
methylation at cytosine residues in CpG dinucleotides, posttranslational modifications of 
amino acids on the amino-terminal tail of histones, and post-transcriptional regulation by 
small non coding RNAS, including microRNAs, is frequent in normal cells during 
embryonic development, imprinting or tissue differentiation104–106 (Figure 1.13). 
Moreover, these epigenetic changes contribute to the different gene expression profiles 
of distinct cell types107. For example, in humans there are several cell types that are 
originated from the same fertilized egg cell, presenting the same DNA. However, each 
one of these cell types have distinct function, due to the inactivation and activation of 
different sets of genes through epigenetic mechanisms108. 
Remarkably, this process can become abnormal, resulting in aberrant changes of gene 
expression, and consequently in several diseases, including cancer107,109. 
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Besides that, epigenetic alterations are also determinant to tumor heterogeneity and 
different treatment responses. An example is the chemoresistance due to 
hypermethylation of the Transcription Factor AP-2 epsilon (TEAP2E) gene, that occurs 
in 51% of CRC110,111. 
 
1.4.1. microRNAs 
MicroRNAs (miRNAs) were discovered in Caenorhabditis elegans in 1993112 and are 
small non-coding ribonucleic acids (RNA) about 21-25 nucleotides in length, which are 
related to regulation of gene expression through complementary binding to 3’untranslated 
region (UTR) of its messenger RNA (mRNA) target molecules. The consequence of this 
binding depends on the complementarity between miRNA and its target. In case of 
complete complementarity, the most probable effect is mRNA degradation. In contrast, 
incomplete complementarity leads to translation inhibition113–115. Therefore, any 
Figure 1.13 Schematic representation of epigenetic modifications. DNA methylation, histone 
modification, and post-transcriptional regulation by noncoding RNA are reversible alterations 
which affect gene expression (from Ahuja et al. 2016). 
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alteration in the regulation of these non-coding RNAs may drive changes in gene 
expression which may lead to silencing or overexpression of many genes. 
miRNAs are encoded either in intronic regions or in intergenic regions and are usually 
transcribed by polymerase II (Pol II), producing primary miRNAs (pri-miRNAs). The 
pri-miRNA is cleaved by DROSHA, which is constituted by two ribonuclease (RNase) 
III domains, generating a precursor miRNA (pre-miRNA) which is exported to the 
cytoplasm, where is recognized by DICER1. This RNase III enzyme cleaves the pre-
miRNA, producing an RNA duplex which later associates with RNA-induced silencing 
complex (RISC). Importantly, this complex will be guided by the guide strand of the 
mature miRNA incorporated in RISC116,117 (Figure 1.14). 
miRNAs have also revealed important in cancer biology, since miRNAs are able to 
control several targets implicated in tumor growth, invasion, angiogenesis, and immune 
invasion. Therefore, the function of miRNAs could be considered as tumor suppressor 
genes or oncogenes, depending on their target. Additionally, recent studies have 
demonstrated different miRNA patterns between normal and tumor tissue, and that these 
patterns are also able to distinct tumor types and their subtypes118. 
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1.4.2. Histone Modifications 
Cells do not express all genes at the same time as gene expression depends on the needs 
of the cell. This is possible due to proteins associated with chromatin called histones, 
which stabilizes the negative charge of DNA and provides stability to the chromatin. 
Histones regulate gene expression through alterations in the chromatin structure, either 
by condensing the chromatin, which leads to gene inactivation, or by stretching the 
chromatin, which results in gene activation104. Therefore, protein binding sites may be 
exposed or masked, and consequently gene expression is altered. 
A group of 8 histones (an octamer) forms the nucleosome, which comprises two of each 
H2A, H2B, H3 and H4 histones. Moreover, there is an additional histone, H1, that works 
as a linker (Figure 1.15A). Each one of these histones is susceptible to suffer 
posttranslational modifications, especially in the N-terminal tails. The impact of these 
modifications, caused by histone methyltransferases (HMT), histone acetyltransferases 
Figure 1.14 miRNA processing. The gene that codifies the miRNA is transcribed originating the 
pri-miRNA. This is processed by DROSHA in the nucleus and, originating the pre-miRNA.It is 
exported to the cytoplasm where it is cleaved by DICER and associated to the RISC complex. 
Lastly, the mature miRNA guides the RISC complex to the target mRNA (from Nelson et al. 
2008). 
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(HAT), histone deacetylases (HDAC), and histone demethylases (HDM), depends on the 
modification- generally acetylation, methylation, phosphorylation, and ubiquitination- 
and residue where it takes place- commonly lysine or arginine residues88,119–121 (Figure 
1.15B). 
 
 
Figure 1.15 Nucleosome assembly and post-translational modification of histone tails. (A) 
A nucleosome is an octamer of histones. (B) Each histone can suffer post-translational 
modifications in its tails (from Chen et al. 2014). 
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Artem Barski has identified histone modifications patterns associated to promoters, 
insulators, enhancers, and transcribed regions. Modifications such as mono methylation 
of histone 3 at lysine 4 (H3K4me1), tri methylation of histone 3 at lysine 4 (H3K4me3), 
and acetylation of histone 3 at lysine 27 (H3K27ac) have been associated to active 
enhancers, active promoters, and active enhancers and promoters, respectively. In 
contrast, tri methylation of histone 3 at lysine 27 (H3K27me3), tri methylation of histone 
3 at lysine 9 (H3K9me3), and tri methylation of histone 3 at lysine 36 (H3K36me3) have 
been associated to repressive chromatin122. 
 
1.4.3. DNA Methylation 
DNA methylation consists in the covalent addition of a methyl group to the 5-carbon of 
a cytosine residue by DNA methyltransferases (DNMT)123. That reaction often takes 
place in CG dinucleotides- CpG sites. These dinucleotides can be located in CpG Islands, 
which are DNA regions constituted by more than 50% of CG dinucleotides in a minimum 
length of 200-500 bases124,125. CpGs are usually methylated in human normal cells and 
located outside of the promoter. Paradoxically, CpG Islands are usually unmethylated and 
overlapping promoter regions (Figure 1.16A)81,108. 
The DNMTs enzyme family includes DNMT1, DNMT3a, and DNMT3B, where DNMT1 
is responsible for maintaining methylation patterns during replication, and DNMT3a and 
DNMT3b are responsible for de novo methylation81,108.  
This epigenetic mechanism is essential during the embryonic development, imprinting, 
X-chromosome inactivation, and suppression of repetitive element transcription. 
Importantly, there are evidences that DNA methylation plays a key role in cancer 
development86,126. 
DNA methylation is often associated with gene inactivation, particularly when it takes 
place at the gene promoter (Figure 1.16B). Nevertheless, there are evidences that 
promoter hypermethylation can also lead to gene activation. The result of DNA 
methylation seems to be dependent on the region where it happens. This means that DNA 
methylation may affect regulatory regions, blocking protein binding sites due to the 
recruitment of methyl-CpG-binding domain (MBD) proteins. If the region affected is an 
activator binding site, the gene will be not expressed. In contrast, hypermethylation of 
gene promoters on repressor binding site, prevents the DNA access, leading to gene 
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expression. Another explanation of gene activation associated with promoter 
hypermethylation, suggested by Bert et. al, is that regional hypermethylation forces the 
activation of alternative transcription start sites (TSS-Figure 1.17)108,125,127. 
 
 
In cancer, this epigenetic mechanism is frequently deregulated, leading to an unbalance 
of gene expression. When aberrant DNA methylation changes- either hypermethylation 
or hypomethylation- occurs in driver genes, the normal cellular function is altered, and 
tumorigenesis may arise. 
Figure 1.16 Hypermethylation can lead to gene inactivation. (A) In normal cells, there is a 
generalized methylation of the gene body, in contrast to a promotor region that is un-methylated. 
(B) In the case of diseases like cancer, promotor region can be aberrantly methylated and the 
region of gene body un-methylated. Consequently, that gene can be silenced. (Adapted from 
McBryan et al. 2014) 
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1.4.4. Epigenetic Alterations and Colorectal Cancer 
Epigenetic events, which may also occur during normal ageing, have been associated with 
higher risk of cancer. In the early 80’s hypomethylation was associated to cancer. 
Moreover, in 1986, hypermethylation of calcitonin was associated with tissue-specific 
gene silencing. Nevertheless, hypermethylation was also associated with inactivation of 
tumor suppressor genes, through observations based on the Rb promoter101. 
Several studies have shown that DNA methylation patterns of many genes become 
aberrant during carcinogenesis, including genes belonging to the Wnt and Ras signaling 
pathways, DNA repair genes, and cell cycle-related genes73. Specifically, in CRC, 
aberrantly methylated genes as Integrin Subunit Alpha 4 (ITGA4), O-6-Methylguanine-
DNA Methyltransferase (MGMT), Solute Carrier Family 5 Member 8 (SLC5A8), and 
Secreted Frizzled Related Protein 2 (SFRP2) have been reported since early stages. 
Therefore, it is evident that methylation is involved in the initiation and progression of 
CRC. However, among all abnormally methylated genes, there is no evidence that a 
specific functional class of genes is more affected during specific steps of CRC initiation 
or progression81. 
In addition, studies have suggested that DNA methylation as well as genetic alterations 
play a role in cancer progression and metastasis. Methylated genes as TIMP 
Metallopeptidase Inhibitor 3 (TIMP3), Inhibitor of DNA Binding 4 (ID4) and Interferon 
Regulatory Factor 8 (IRF8) are more frequent in advanced CRC than in adenomas, 
Figure 1.17 Promoter hypermethylation can be associated with gene activation. (A) 
Promoter hypermethylation can happen in a region of repressors binding. Hence, when 
hypermethylation occurs, the transcriptional repressor is blocked, leading to abnormal gene 
activation. (B) Promoter hypermethylation can lead to the gene activation through alternative 
TSS. (Adapted from Bert et al. 2013) 
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providing clonal growth advantage. Despite association to advanced stages, DNA 
methylation seems to be most prevalent in CRC initiation rather than in its progression81. 
 
1.4.5. Epigenetic biomarkers as predictors of clinical outcome  
A biomarker is any substance, structure, or process that can be estimated, and used in 
order to identify normal biological processes, pathogenic processes, treatment responses, 
or evolution of the disease128. Hence, epigenetic biomarkers could be useful in the clinic 
for diagnosis, prognosis or prediction of responsiveness to therapy. 
Specifically, in CRC, in spite of efforts to identify new biomarkers capable to detect or 
predict progression and therapy response, there is a lack of accurate biomarkers. 
Moreover, as reported before, the detection of CRC in early stages is crucial to the 
efficiency of the treatment. 
Therefore, measuring DNA methylation levels of specific sites can be a potential 
biomarker, since DNA methylation patterns are found usually altered in CRC. Not only 
that, DNA methylation levels can be detected through non-invasive methods, such as 
evaluation of tumor-derived cell-free from blood or feces, making it a good 
biomarker129,130. 
Until now, few epigenetic biomarkers have been reported in CRC, including aberrant 
methylation of Septin 9 (SEPT9) detected in plasma (sensitivity and specificity of almost 
90%), methylation of SFRP2 detected in serum and fecal DNA (sensitivity of almost 
67%)131, methylation of Thrombomodulin (THBD) detected in blood (sensitivity of 74% 
to stage I/II CRC at a specificity of 80%)132 and methylation of Syndecan 2 (SDC2) also 
detected in blood (sensitivity of 92% for stage I)133. An epigenetic biomarker based on 
aberrant methylation of Vimentin (VIM) is currently commercialized in  the United States 
for early detection of CRC with 83% of sensitivity and 82% of specificity81. Among all 
existent epigenetic biomarkers, two meta-analysis estimate that the sensitivity to diagnose 
CRC and adenomas is about 62%-75%134,135. 
 
1.5. Databases Analysis and Statistic Methodologies 
In the last years, the amount of data available in public repositories has increased 
enormously. The Cancer Genome Atlas (TCGA), The National Center for Biotechnology 
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Information (NCBI), Ensembl, Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC), and Kyoto Encyclopedia of Genes and Genomes (KEGG) are 
good examples of these repositories where vast amounts of clinical and biological 
information is present with relatively easy accessibility136,137. 
Indeed, before the new computational era and the web repositories, the costs and time 
spent collecting data could restrict scientific production. Nowadays, the improvement of 
online platforms not only allows for its access anywhere in the world but also significantly 
reduced the time spent in the data processing (Figure 1.18)138,139. 
However, to handle the amount of available data can be a challenge. Therefore, 
researchers from different fields of knowledge have been developing bioinformatic 
approaches combined with statistical analysis139. This promotes the creation of 
methodologies that can test hypothesis to be validated by inferential statistics with the 
help of computational tools136. Some of these tools comprise different programming 
languages (including R language used in the present work) since statistical software has 
its limitations regarding the management and processing of big data140,141. 
Moreover, TCGA, the principal repository of data collection used in these studies has 
become an important repository for cancer research, since it stores more than 2.5 
petabytes of information, including genetic, epigenetic and clinical data, allowing for the 
analysis of more than 440 thousand variables (e.g. in case of DNA methylation).  
Also, other methodological strategies were implemented in order to validate our analysis 
that included:  
1.  Univariate approaches to analyze the population of the study, including the 
socio-demographic and clinical characterization; 
2. Bivariate approaches to analyze the linear association of gene expression and 
DNA methylation in order to select which genes and CpG sites are differentially 
expressed and methylated, respectively; 
3. Multivariate approaches to observe the relationship between genes and CpG sites 
selected, and the sample distribution. 
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This characterization allowed to identify genes and CpG sites that can discriminate tumor 
samples from normal samples, and, subsequently, among different stages, to identify all 
significant associations between gene expression and DNA methylation. Finally, using 
multivariate approaches, we aimed to prove that the distribution of samples is able to 
reflect the intrinsic distancing of gene expression of DNA methylation of that samples, 
which were previously selected. 
  
Figure 1.18 A network of data availability. Data can be upload and download from different 
databases to be used in different research projects (adapted from 
https://cbiit.cancer.gov/ncip/cancer-research-data-commons). 
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2. CHAPTER II- OBJECTIVES 
Even though several studies have identified aberrant expression of several genes in CRC 
to be associated to epigenetic events, including aberrant DNA methylation, there is still a 
lot to know about how DNA methylation impacts gene expression during CRC 
carcinogenesis. Moreover, there is a lack of biomarkers that can accurately identify 
patients with early stages of CRC or predict patient outcome. Therefore, the identification 
of new biomarkers that play a key role in the initiation and progression of CRC might 
improve personalized treatments. 
Here, we hypothesize that there is an epigenetic roadmap in CRC progression. Therefore, 
we: 
1. Performed a genome-wide analysis of both DNA methylation and gene 
expression, contributing to the knowledge of epigenetic dynamics on CRC; 
2. DNA methylation and gene expression of CRC patients in different stages of 
its progression through developing a Bioinformatics based tool (script); 
3. Identified epigenetic mutations responsible for CRC initiation and progression; 
4. Identified potential epigenetic biomarkers to help in the diagnosis and 
prediction of CRC progression. 
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3. CHAPTER III- MATERIALS AND METHODS 
 
 
3.1. Data Collection 
We analyzed whole-genome DNA methylation (Illumina Infinium HumanMethylation 
450K array) and gene expression (Illumina HiSeq) of CRC patients (“TCGA-COAD” 
and “TCGA-READ”) publicly available in The Cancer Genome Atlas database (TCGA; 
http://cancergenome.nih.gov/). The data was obtained through TCGAbiolinks package 
using the functions: GDCquery, GDCdownload, and GDCprepare142. 
 
3.1.1. The Cancer Genome Atlas 
TCGA is an American database funded by National Cancer Institute (NCI) from the 
National Institute of Health (NIH) and the National Human Genome Research Institute 
(NHGRI) with the main aim to understand the genetics of cancer. TCGA has over 2.5 
petabytes of data, aggregating 33 different tumor types, including 10 rare cancers, based 
on paired tumor and normal tissue sets collected from 11,000 patients143. Importantly, it 
means that normal tissue samples were obtained from cancer patients (Figure 3.1). 
 
Figure 3.1 TCGA by numbers. TCGA provides data for different tumor types regarding a 
significant amount of patients (adapted from https://cancergenome.nih.gov/abouttcga). 
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a. Gene Expression 
Gene expression values were generated through Illumina HiSeq 2000 RNA Sequencing 
platform by the University of North Carolina TCGA genome characterization center. 
These values were normalized (RSEM normalized count) and transformed by the 
application of base 2 logarithm to the expression measures plus one. The purpose of this 
transformation is to linearize the relationship between gene expression and DNA 
methylation144. Furthermore, UCSC Xena HUGO probeMap was used to map genes. 
 
b. DNA Methylation 
DNA methylation values (beta values) were measured experimentally through Illumina 
Infinium HumanMethylation450K array and were noted using BeadStudio software. The 
beta values range from 0 to 1, depending on the intensity ratio between the methylated 
bead type to the combined locus intensity, meaning that higher beta values correspond to 
higher methylation levels whereas lower beta values correspond to lower methylation 
levels145. 
 
c. TCGAbiolinks Package 
To download clinical data, from both DNA methylation and gene expression datasets for 
both colon (TCGA-COAD) and rectum (TCGA-READ) cohorts, we used the 
Bioconductor package TCGAbiolinks version 2.7.2 available for R programming140. The 
package is a software tool developed to query, download and analyze genomic and 
epigenomic data, once TCGA is a challenge for bioinformaticians, clinicians and 
molecular biologists. When compared to other tools developed to analyze TCGA open 
access data, TCGAbiolinks is the most complete package142. 
 
3.2. Patient Selection 
In order to group CRC patients, the clinical information was imported to R using 
GDCquery_clinic function provided by TCGAbiolinks package or were obtained online 
(https://xena.ucsc.edu/). 
The patients were separated into 5 groups according to CRC staging: Solid Tissue 
Normal, and stage I-IV (Primary Solid Tumor). To perform this analysis, only patients 
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with tumor stage information, DNA methylation and gene expression data were included 
(Figure 3.2A, Figure 3.2B). 
 
Figure 3.2 Sample selection using R programming. DNA methylation and gene expression 
data were obtained for the groups of patients: (A) normal samples, and (B) primary tumor 
samples. 
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Therefore, the analysis of TCGA-COAD and TCGA-READ cohorts was based on 21 
Solid Tissue Normal patients, and 347 Primary Solid Tumor (54 stage I, 131 stage II, 111 
stage III, and 51 stage IV). Importantly, few patients had DNA methylation measures 
from more than one sample. In these cases (duplicated cases), the DNA methylation 
measure was substituted by the median value of duplicated cases for each methylation 
probe (Figure 3.3). 
 
 
3.3. Study Pipeline 
After patient selection, we analyzed both DNA methylation and gene expression data to 
identify which CpG sites and genes were differentially methylated and expressed in 
Primary Solid Tumor comparatively to Solid Tissue Normal. 
Initially, absence of gene location, or probe identification were exclusion criteria for CpG 
sites selection whereas absence of gene name was exclusion criteria for gene selection. 
Importantly, before any statistical analysis, outlier values were removed from both 
expression and methylation databases. Then the set of selected genes and CpG sites were 
analyzed (Figure 3.4). 
Figure 3.3 The approach to remove duplicated cases. DNA methylation measurements of 
different samples from the same patient was substituted by the median value of duplicated cases 
for each methylation CpG site. 
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Secondly, a statistical analysis was performed to identify if there is statistical evidence 
for differences on gene expression/ DNA methylation between normal and tumor tissue 
samples of each stage of the CRC. At that point, only genes/CpG sites with false discovery 
rate (FDR) lower than 5% were considered (Figure 3.4). 
Then, the mean for each gene/CpG site was calculated for normal and tumor samples 
(calculated separately depending on disease stage), aiming to measure the base 2 
logarithm of fold-change (referred only as fold-change) and Δβ values, respectively. 
Thus, genes with fold-change absolute value higher than 1.5 and CpG sites with Δβ 
absolute value higher than 0.2 were considered as differentially expressed and methylated 
between normal and tumor samples, respectively. Importantly, only differentially 
expressed genes which contained CpG sites differentially methylated were considered. 
Similarly, only CpG sites located in genes differentially expressed were considered 
(Figure 3.4). 
 
 
Lastly, a Pearson correlation test was performed as criteria of both CpG sites and genes 
selection. This analysis was executed aiming to identify a relationship between 
Figure 3.4 Study Pipeline. Both whole-genome Illumina HiSeq and Illumina Infinium 
HumanMethylation 450K array data were analyzed. Firstly, were selected genes and CpG sites 
with statistic differences (FDR cut-off < 0.05). Then, an additional cut-off was applied for gene 
expression values- fold-change absolute value higher than 1.5- and for DNA methylation- Δβ 
absolute value higher than 0.2. After, only genes with CpG sites differentially methylated as well 
as CpG sites located in differentially expressed genes were admitted. At last, Pearson coefficient 
was measured, and a p-value cut-off was applied (p-value <0.05). 
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methylation and expression levels in tumor tissue. At this step, a p-value cut-off lower 
than 0.05 was established (Figure 3.4). 
Moreover, enrichR R package was used to clarify in which pathways (KEGG 2016) 
selected genes were involved. The same package was used to identify enriched biological 
processes (GO Biological Process 2018)146. 
Another package available for R software, RISmed, was used to investigate which 
selected genes had not yet been reported in PubMed database as associated with CRC or 
with cancer in general147. 
Thereafter, in order to identify potential good diagnostic biomarkers that could 
discriminate tumor from normal tissue, a receiver operating characteristic (ROC) curve 
analysis was performed using pROC R package148. Here, it was applied a cut-off, in which 
it was considered as potential good diagnostic biomarkers genes/CpG sites with an area 
under the curve (AUC) higher than 0.8149. Then, survival R packages was used to perform 
Cox regression analysis in order to identify prognostic biomarkers (overall survival and 
recurrence free survival)150,151. In this analysis, the threshold to divide patients into two 
groups was based on the median, and a p-value cut-off at 0.05 was considered. 
   
3.4. Statistical Testing 
In order to identify if there were any evidences of statistically significance differences 
between Solid Tissue Normal and Primary Solid Tumor, test hypothesis were formulated, 
and statistical hypothesis tests were performed152. The main aim of statistical hypothesis 
tests is to achieve characteristics of a certain population by statistical inference153. This 
means that statistical hypothesis tests are performed based on a sample and extrapolated 
to a population. 
Therefore, statistical testing implies the formulation of a null hypothesis, the selection of 
the most appropriate statistical test, and the p-value estimation to asses if the null 
hypothesis is true. The null hypothesis generally asserts that there are no differences 
between our groups. In opposition, the alternative hypothesis sustains that there are 
differences between our groups, and that those differences did not arise due to chance. 
The most common way to decide if the null hypothesis is rejected is based on p-value154–
156.  
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The choice of statistical test depends on the data distribution. If the data are normally 
distributed, parametric tests are most adequate. On the other hand, if the data are “free 
distributed”, nonparametric tests should be used. Parametric methods are based on mean 
estimator, being more powerful. In contrast, nonparametric methods use the median, 
being more robust, especially in case of existence of outliers157. 
All statistical analysis were performed using functions provided by available packages 
for R programming140. Importantly, in all statistical analysis, it was used a p-value <0.05 
as the significance level. 
 
3.4.1. Handling Outliers 
Experimental data can present observations with values deviated from the other ones- 
outliers. Indeed, these cases may influence our analysis. For example, in the concrete case 
of the current study, the presence of outliers can influence the fold-change measured. 
Hence, the decision if a specific gene is or not differentially expressed can be biased. 
Therefore, to deal with this issue, outliers should be identified and properly handled158–
160. 
Here, outliers were assessed using boxplot.stats function provided by R base140. 
Moreover, these values were not replaced, meaning that missing values were introduced 
in our data (Figure 3.5). 
 
 
3.4.2. Shapiro-Wilk Normality Test 
Shapiro test was used to assess whether the sample is normally distributed. The null 
hypothesis assumes that the population is normally distributed, meaning that lower p-
values suggest that the sample is not normally distributed whereas higher p-values suggest 
that the sample is normally distributed. Importantly, compared to other tests to assess 
Figure 3.5 Function to remove outliers. Outlier values were substituted by missing data. 
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normality, Shapiro-Wilk test is considered the be the most powerful test, independently 
of either the size or the type of distribution of the sample161. 
Here, the function shapiro.test provided by stats package was used140. Importantly, few 
variables were excluded from this analysis due to: 
a. missing data- only variables with at least 3 non-missing values were 
considered161; 
b. all non-missing data to be equal 0. 
 
3.4.3. Paired and Unpaired Two-Sample Tests 
The Wilcoxon rank sum test, also known as Mann-Whitney U test, is a non-parametric 
test which was used with the aim to compare two samples (e.g. to compare DNA 
methylation measures of both normal and tumor tissue) that are not normally distributed. 
The null hypothesis is that the distribution of both groups is the same162. By contrast, 
when we intend to compare two normally distributed samples, a parametric test was 
applied. If both samples are normally distributed and they had equal variances, the 
unpaired Student’s t test was applied. Otherwise, when samples were normally 
distributed, but they had unequal variances, the Welch test was applied163. The null 
hypothesis in t test is that the mean of both samples is equal164. 
In order to perform both Wilcoxon signed-rank and t test, wilcox.test (Figure 3.6A) and 
t.test (Figure 3.6B) functions was used140. Here, it was only considered variables with 
two or more observations in both samples (normal and tumor tissue). 
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3.4.4. Levene Test 
The Levene test was used to assess the equality of variances of two samples. This test 
was performed before the implementation of t test to decide if the Welch test should be 
applied. The null hypothesis is that the variances of two samples are equal165. 
Levene test was implemented using the leveneTest function provided by car R package 
(Figure 3.7)166. 
 
 
Figure 3.7 Adapted function to perform the Levene test. 
Figure 3.6 Adapted functions to compare two-samples. (A) Function to perform a t-test 
considering the variance homogeneity. (B) Function to perform Wilcoxon signed-rank test. 
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3.4.5. Correction for Multiple Testing 
Many simultaneous statistical tests might originate p-values less than the critical value by 
chance, hence resulting in the rejection of null hypothesis even if it is true (false positive 
or type I error). In case of a p-value of 0.05, when 100 null hypotheses are simultaneous 
tested, the chance of commit a type I error is 5%. Due to this fact, each p-value must be 
corrected. One approach to adjust the p-value is using the false discovery rate (FDR) 
method, which corrects the falsely rejected hypothesis155,167. 
In order to correct multiple testing effect, p-values obtained were corrected by FDR 
method using the function p.adjust provided by stats package140. 
 
3.4.6. Pearson Correlation 
Pearson correlation test is a parametric statistic test which aims to detect if two pared 
continuous variables are linearly associated. The relationship between the variables are 
measured by correlation coefficient that range from -1 (perfect negative correlation) to 1 
(perfect positive correlation). A correlation coefficient of 0 means that there is not a linear 
correlation between the variables (Table 3.1). Importantly, correlation analysis do not 
indicate which variable vary in response to the other one168–170. 
 
Table 3.1 Correlation coefficient interpretation. The relationship between two pared 
continuous variables can be measured by correlation coefficient. This coefficient ranges from -1 
to 1, being dependent on the degree of association between these variables (adapted from Mukaka 
et al. 2012). 
 
 
 
 
                                    1Absolute value 
 
In this specific case, the Pearson correlation was performed to identify which DNA 
methylation variations are associated to unbalance in gene expression in Primary Solid 
|Correlation Coefficient|1  Meaning 
0.00 – 0.30  Negligible correlation 
0.30 – 0.50  Low correlation 
0.50 – 0.70  Moderate correlation 
0.70 – 0.90  High correlation 
0.90 – 1.00  Very high correlation 
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Tumor. The null hypothesis is that correlation coefficient is 0155. To perform Pearson 
correlation, the function cor.test provided by stats R package was used140. 
 
3.4.7. Receiver operating characteristic (ROC) curve analysis 
ROC curve analysis was used as a technique to measure the quality of a diagnostic 
biomarker (e.g. identify CpG sites as a potential diagnostic tool). This curve is represented 
based on the true positive fraction (TPF), the same of sensitivity, and false positive 
fraction (FPF), given by 1 – specificity. The TPF is the ratio between the number of true 
positive decision and the number of actually positive cases. Otherwise, FPF is the 
ratio/division between the number of false positive decisions (considered as positive, but 
actually are negative) and the number of actually positive cases. Therefore, each 
coordinate (x,y) in a plot of the ROC curve corresponds to a pair of TPF and FPF171. 
Moreover, the relationship between these two measures- accuracy- can be determined 
through the area under the ROC curve (AUC). These accuracy measure range from 0.5 to 
1. As described in the Table 3.2, lower AUC values represent an inaccurate test -bad 
diagnostic tool- whereas higher AUC values represent an accurate test- good diagnostic 
tool149,172. 
 
Table 3.2 Classification of the diagnostic accuracy. The area under the ROC curve, an accuracy 
measure, is used to classify the diagnosis potential of a specific tool (Khouli et al. 2009). 
 
 
 
 
The ROC curve analysis was implemented using the roc function provided by pROC R 
package148. Importantly, an AUC cut-off of 0.8 was established to consider good 
biomarkers149. 
 
Area Under the Curve (AUC)  Meaning 
0.5 - 0.6  Failed 
0.6 – 0.7  Poor 
0.7 – 0.8  Fair 
0.8 – 0.9  Good 
0.9 - 1  Excellent 
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3.4.8. Overall Survival and Recurrence Free Survival Analysis 
The prognostic ability of selected genes and CpG sites was tested fitting a Kaplan-Meier 
(KM) analysis, a logrank test, and a Cox proportional hazards regression model. This 
approach compares the survival time, with possible censoring, of two groups divided 
according to a specific threshold of the predictor variable. Firstly, the KM, an estimator 
that was used to determine the survival function for our two groups (better prognosis and 
worst prognosis), was drawn173,174. Then, it was used the logrank test in order to compare 
the survival functions of both groups. This test is a non-parametric test where the null 
hypothesis is that the distribution of both functions is the same174,175. 
Finally, the effect of the selected factor (methylation values of a CpG site or expression 
values of a gene) on the survival was measured through hazard ratio (HR). If a hazard 
ratio is equal 1, that predictor variable has no effect on survival. A hazard ratio lower than 
1 is a bad prognostic factor for group 1 when compared to group 2 whereas a hazard ratio 
higher than 1 is a good prognostic factor for group 1 when compared to group 2176–178. 
This analysis was performed using coxph function provided by survival R package. Then, 
to estimate the survival/recurrence proportion, it was used the surfit function provided by 
survival R package. Kaplan-Meier curves were done using the ggsurvplot function 
provided by survminer R package150,151,179. Importantly, the threshold was based on the 
median value of the predictor variable. 
 
3.4.9. HJ-Biplot and Hierarchical Clusters 
HJ-Biplot is a data reduction technique to analyze, in a multivariate perspective, the 
samples distribution considering all relationships of variables. A hierarchical cluster 
analysis156 was performed considering the patient coordinates180. Thus, we used the Ward 
method to aggregate samples in clusters considering the square Euclidean distance. 
Moreover, in this approach was fixed the contributions, of factor to the element, over than 
0.7. This contribution allows to know which variables are more directly related to each 
axis, and, consequently, it also allows to identify which variables are the most responsible 
by distributing the individuals on a reduced space, for posterior orthogonal projections in 
each variable. Importantly, it was only selected genes which have CpG sites with 
contributions of factor to the element over 0.7, as well as CpG sites which are located in 
genes with contributions of factor to the element over 0.7. 
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HJ-Biplot was implemented using the function HJ.Biplot provided by MultBiplotR R 
package. The Analysis of Hierarchical Clusters was executed using the function 
AddCluster2Biplot provided by the same R package181. Importantly, this technique does 
not deal with missing data. Hence, missing observations were replaced by the median 
value of the respective variable. 
 
3.5. Citation Tool 
RISmed is a text data mining package able to interact with Pubmed, a public query 
database of scientific literature. This package allows to count how many times a term was 
referred in Pubmed abstracts and, when possible, in PubMed articles147. 
EUtilsSummary and QueryCount functions were used to investigate which genes were 
mentioned in both CRC and cancer in general on Pubmed published articles from 1787 
to June 2018, and how many times have been mentioned (Figure 3.8A). The keywords 
used include “cancer”, “colorectal cancer”, “rectum cancer”, and “colon cancer”. 
Importantly, the function keggGet, provided by KEGGREST package available for R 
software, was also used to identify all names given to each gene (Figure 3.8B)182. All 
these names were used in our analysis. 
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3.6. Enrichment Analysis 
To better understand the functional profile of a set of genes differentially expressed and 
methylated in our CRC cohort, it was performed an enrichment analysis. In this step, the 
function enrichr, provided by enrichR package, was used to obtain and display the most 
statistically significant enriched pathways (KEGG_2016) and biological processes 
(GO_Biological_Process_2018)146. 
  
Figure 3.8 Functions to obtain the number of citations in PubMed for each gene. (A) 
Function to obtain all designations for each gene. (B) Function of obtain the total number of 
citations of each gene in association with a cancer term. 
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4. CHAPTER IV- RESULTS 
 
 
4.1. Clinical Features 
CRC patients analyzed in this study were characterized according to the parameters 
showed in Table 4.1. The clinical data was exported from TCGA website, being 
processed and analyzed through R programming140. 
Stage I patients are a mean age of 66 years old. Approximately 60% of our group is 
constituted by male, and 40% of female patients. Almost all patients are white- 76%- 
against 15% of black or African American. Additionally, colon is the more affected region 
comprising 80% of all cases. The anatomic subdivision more common is the cecum 
(35%), being splenic flexure the less common (2%-Table 4.1). 
Moreover, the mean age of stage II CRC is about 66 years old. In this stage, the genders 
are more balanced, with 51% of males and 49% of females. Regarding to the race, it is 
observed that white patients constitute the great majority (68%). In addition, colon is the 
most frequently affected region (81%), being sigmoid colon the most predominant 
subdivision (18%-Table 4.1). 
Furthermore, in stage III, was observed a mean age of 63 years old. Additionally, 55% of 
all patients are male against 45% of females. In terms of race, 76% are white patients, 
keeping the patterns observed in the other stages. Moreover, it is observed that in 70% of 
all patients, the tumor site is colon against 30% of rectum. Regarding to the anatomic 
subdivision, as in the stage I, cecum is the region most afflicted (Table 4.1). 
Regarding to stage IV, the mean age of these patients is 61 years old. In addition, 57% 
are male patients whereas 43% are females. The predominant race continues to be white 
patients (71%). Moreover, 75% of all cases are colon tumor, being sigmoid colon, the 
most anatomic subdivision affected (27%-Table 4.1). 
At last, the patients with normal samples are a mean age of 68 years old, and 24% are 
male patients. Furthermore, 48% of these patients are white, 14% are black or african 
American, and 38% have no information available about their race. Moreover, as normal 
samples are collected from patients with the disease, there are tumor related information 
about these patients. Specifically, about 90% of them are colon cancer, and sigmoid colon 
is the anatomic subdivision most affected (38%-Table 4.1). 
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Table 4.1 Descriptive statistics about patients, as well as the distribution of patients by stage. 
1standard deviation 
 
4.2. Epigenetic Roadmap in Colorectal Cancer 
Aiming to investigate which CpG sites are differentially methylated in tumor tissue when 
compared to normal tissue, we performed a comparative analysis between normal tissue 
and each stage of CRC. 
 
Groups 
n (%) 
 
Normal 
21 (5.7) 
Stage I 
54 (14.7) 
Stage II 
131 (35.6) 
Stage III 
111 (30.1) 
Stage IV 
51 (13.9) 
Age (mean ± sd1 years)  68 ± 13 66 ± 13 66 ± 13 63 ± 13 61 ± 13 
< 65 years old   7 (33%) 24 (44%) 57 (44%) 61 (55%) 31 (61%) 
> 65 years old  14 (67%) 30 (56%) 74 (56%) 50 (45%) 20 (39%) 
Gender       
Male  12 (57%) 32 (59%) 67 (51%) 61 (55%) 29 (57%) 
Female  9 (43%) 22 (41%) 64 (49%) 50 (45%) 22 (43%) 
Race       
Black or African 
American 
 
3 (14%) 8 (15%) 19 (15%) 22 (20%) 11 (22%) 
American Indian or 
Alaska Native 
 
0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 
White  10 (48%) 41 (76%) 89 (68%) 85 (76%) 36 (70%) 
Asian  0 (0%) 0 (0%) 11 (8%) 1 (1%) 0 (0%) 
Not Reported  8 (38%) 5  (9%) 12 (9%) 2 (2%) 4 (8%) 
Anatomic Subdivision       
Ascending Colon  2 (10%) 6 (11%) 24 (18%) 10 (9%) 6 (12%) 
Descending Colon  1 (5%) 2 (4%) 5 (4%) 5 (4%) 2 (4%) 
Cecum  4 (18%) 19 (35%) 21 (16%) 23 (21%) 9 (17%) 
Hepatic Flexure  2 (10%) 2 (4%) 7 (5%) 7 (6%) 1 (2%) 
Rectosigmoid Junction  0 (0%) 6 (11%) 10 (8%) 17 (15%) 7(14%) 
Rectum  2 (10%) 4 (7%) 14 (11%) 15 (14%) 6 (12%) 
Sigmoid Colon  8 (37%) 10 (18%) 33 (25%) 22 (20%) 14 (27%) 
Splenic Flexure  0 (0%) 1 (2%) 3 (2%) 0 (0%) 1 (2%) 
Transverse Colon  0 (0%) 3 (6%) 9 (7%) 9 (8%) 1 (2%) 
Not Reported  2 (10%) 1 (2%) 5 (4%) 3 (3%) 4 (8%) 
Tumor Site       
Colon  
19 (90%) 43 (79%) 
106 
(81%) 
78 (70%) 38 (75%) 
Rectum  2 (10%) 10 (19%) 25 (19%) 33 (30%) 12 (25%) 
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We analyzed 364,643 probes and 20,502 genes, from CRC patients in different stages of 
the disease. To consider genes as differentially expressed and CpG probes as differentially 
methylated a p-value cut-off lower than 0.05, a fold-change absolute value cut-off higher 
than 1.5, and a Δβ absolute value cut-off higher than 0.2 were defined (Figure 3.4, Figure 
4.1). 
The comparative analysis with normal tissue suggested that 4,268 CpG sites 
corresponding to 681 genes are differentially methylated and expressed in stage I of the 
disease (Figure 4.1). Additionally, the correlation analysis shows that DNA methylation 
alterations of 924 CpG sites are correlated to gene expression changes of 307 genes 
(Figure 4.1, Appendix 1, and Appendix 2). The majority of these CpG sites are 
hypermethylated in tumor tissue (597 hypermethylated and 327 hypomethylated- Figure 
4.2A1, Appendix 1) and associated to down-regulated genes (226 down-regulated and 81 
up-regulated, Appendix 2). Interestingly, when we determine the position of those CpG 
sites across the 307 genes, we found that the majority of them are in the gene body 
(43.8%), followed by regions near the TSS (34.6%). The five prime untranslated region 
(5’UTR), three prime untranslated region (3’UTR), and first exon are regions with less 
differentially methylated CpG sites (10.4%, 4.7%, and 6.5%, respectively; Figure 4.3A). 
Figure 4.1 Study pipeline indicating CpG sites and genes selected for each stage. The 
pipeline presented at Figure 3.2 was applied to CpG sites and genes available in the TCGA 
database. Here, it is shown how many CpG sites and genes were selected in each step of that 
pipeline. 
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Additionally, from the 924 CpG sites, 543 are negatively correlated with gene expression, 
while 381 are positively correlated (Figure 4.2A2, Appendix 1). 
Moreover, when we investigate the top 15most differentially expressed genes (Table 4.2), 
we found that most genes are up-regulated in tumor tissue, excepting CACNG5, GABRG1 
and HTR3B, with an absolute fold-change value ranging from 4.47 to 6.62. Interestingly, 
altogether these genes have 27 CpG sites differentially methylated associated with them 
(0.20 < |Δβ| < 0.41), which are linearly correlated with gene expression levels (0.27 < |ρ| 
< 0.64). Moreover, our analysis shows that both SOX14 and HTR3B are strongly regulated 
by DNA methylation. Specifically, SOX14 is negatively correlated to the methylation 
levels of 6 CpG sites whilst HTR3B is positively correlated with 4 CpG sites in CRC 
tissue (Appendix 1, Appendix 2). 
Regarding to stage II of the disease, our analysis suggested that 3,506 CpG sites located 
throughout 580 differentially expressed genes are differentially methylated compared to 
normal tissue (Figure 4.1). However, only 1,814 CpG sites (1,366 hypermethylated, and 
448 hypomethylated- Figure 4.2B1, Appendix 3) are significantly correlated to 400 genes 
(294 down-regulated, and 106 up-regulated- Figure 4.1, Appendix 4), being 1,305 
negatively correlated and 509 positively correlated (Figure 4.2B2, Appendix 3). 
Furthermore, the majority of CpG sites selected are located in the gene body (36.5%), 
TSS1500 (23.6%), and TSS200 (19.5%). Only 10.1% are in the 5’UTR, 6.4% in the first 
exon, and 3.9% in the 3’UTR region (Figure 4.3B). 
Additionally, our analysis identified genes represented in Table 4.2 as the top 15 genes 
more differentially expressed in tumor tissue when compared to normal tissue (4.47 < 
|fold-change| < 6.57). These top 15 genes are linearly correlated to methylation levels of 
33 CpG sites (0.21 < |Δβ| < 0.40; 0.18 < |ρ| < 0.66). Surprisingly, PTF1A is negatively 
correlated with methylation levels of 13 CpG sites (Appendix 3, Appendix 4).  
Additionally, from normal tissue to stage III, 2,522 CpG sites located on 502 genes are 
statistically differentially methylated and expressed (Figure 4.1). Moreover, 1,169 CpG 
sites (758 hypermethylated and 412 hypomethylated- Appendix 5) are also correlated to 
gene expression changes of 305 genes (205 down-regulated and 102 up-regulated- Figure 
4.1, Figure 4.2C1, and Appendix 6), being 690 negatively correlated and 479 positively 
correlated (Figure 4.2C2, Appendix 5). Additionally, these CpG sites distributed along 
the gene, being the gene body (39.9%) the most enriched region, followed by TSS1500 
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(21%), TSS200 (20.8%), 5’UTR (9.1%), first exon (4.7%), and 3’UTR (4.5%, Figure 
4.3C). 
 
 
Figure 4.2 Characterization of CpG sites differentially methylated throughout CRC 
development. Status of both CpG sites and the respective gene in (A1) stage I, (B1) stage II, 
(C1) stage III, and (D1) stage IV of CRC development. Moreover, it is also represented the 
Pearson correlation- between gene expression and methylation values of each CpG site- 
distribution in (A2) stage I, (B2) stage II, (C2) stage III, and (D2) stage IV. 
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Furthermore, this analysis reveals that the top 15 genes more differentially expressed on 
stage III, represented in the Table 4.2, have absolute fold change values ranging from 
4.34 to 6.79. These genes are correlated with methylation levels of 34 CpG sites (0.20 < 
|Δβ| < 0.41; 0.19 < |ρ| < 0.90). Among all these genes, PTF1A is the gene correlated with 
more CpG sites (11 CpG sites- Appendix 5, Appendix 6). 
 
 
Ultimately, it was identified 2,277 CpG sites related to 518 genes differentially expressed 
in stage IV when compared to normal tissue (Figure 4.1). From these set of genes and 
Figure 4.3 Localization of CpG sites differentially methylated in the gene. Distribution of 
CpG sites differentially methylated (A) in stage I, (B) stage II, (C) stage III, and (C) stage IV. 
Only CpG sites with one gene location were taken into account. TSS1500 and TSS200: probes 
located within 1500 and 200 base pairs from the transcription start site, respectively; 5’UTR 
and 3’UTR: five and three prime untranslated regions, respectively. 
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CpG sites, were identified 618 CpG sites (266 hypermethylated, and 352 
hypomethylated- Appendix 7) which are statistically correlated to gene expression of 233 
genes (146 down-regulated, and 87 up-regulated-Figure 4.1, Figure 4.2D1, and 
Appendix 8), being 288 negatively correlated and 330 positively correlated (Figure 
4.2D2, Appendix 7). Similarly, to previously stages, the gene body (45.8%) is where most 
events occur, followed by TSS1500 (18%), TSS200 (14.5%), 5’UTR (12%), 3’UTR 
(5.2%), and first exon (4.5%; Figure 4.3D). 
 
Table 4.2 The top 15 most differentially expressed genes for each stage of the disease 
 
 
 
 
 
 
 
 
 
In the Table 4.2, the top 15 genes, which have absolute fold change values ranging from 
4.51 to 5.75, were identified. Additionally, 40 CpG sites are correlated either positively 
or negatively with these top 15 genes (0.20 < |Δβ| < 0.43; 0.28 < |ρ| < 0.90). Specifically, 
ELF5 is strongly negatively correlated with methylation levels of 9 CpG sites as well as 
FGF3 (Appendix 7, Appendix 8). 
 
4.3. Nervous System Related Functions are Enriched in CRC 
Aiming to clarify the biological relevance of genes involved in cancer progression, a 
functional enrichment analysis was performed using enrichR package available for R 
software146. 
Stage I Stage II Stage III Stage IV 
    
FEZF1 FEZF1 FEZF1 KRTAP3-1 
SOX14 SOX14 LOC84931 ZIC5 
LOC84931 SPRR1A SOX14 PTF1A 
SPRR1A LOC84931 SPRR1B DKK4 
GBX2 GBX2 C14orf105 NKX2-8 
ZIC5 ZIC5 ZIC5 DIRC1 
CACNG5 C14orf105 KRTAP3-1 SPRR3 
PGLYRP3 SPRR3 DIRC1 HTR2C 
GABRG1 DKK4 PTF1A LY6G6E 
SEMG2 DIRC1 ONECUT3 HOXC13 
ONECUT3 OTOP3 ELF5 TBX5 
HTR3B PTF1A PGLYRP3 ELF5 
DIRC1 SEMG2 NXPH1 SPERT 
SPRR3 KRTAP3-1 LY6G6E ONECUT3 
KRTAP3-1 PGLYRP3 NKX2-8 FGF3 
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This analysis showed that the great majority of enriched pathways are common across 
CRC progression. In detail, “Neuroactive ligand-receptor interaction” is significantly 
enriched in all stages, being the most significantly enriched pathway (adjusted p-value < 
0.05) in all stages (Figure 4.4, Appendix 9, Appendix 10, Appendix 11, and Appendix 
12). The nicotine addiction pathway is also present among all stages of the disease. 
Salivary secretion is significantly enriched in both stages II and IV, cAMP signaling 
pathway is also significantly enriched in stage II, and amyotrophic lateral sclerosis (ALS) 
is enriched in stage I (Figure 4.4, Appendix 9, Appendix 10, Appendix 11, and Appendix 
12). 
 
 
Moreover, when the focus is on the top 9 of the most significantly enriched biological 
process of each stage (adjusted p-value lower than 0.05) gene ontology (GO), we found 
“dopaminergic neuron differentiation” as the most enriched biological process, 
considering the ratio of overlapped genes. Interestingly, this is significantly enriched in 
all stages of CRC development, although stage II, and stage III are stages with more genes 
Figure 4.4 Enriched pathways across colorectal cancer development. The most significant 
enriched pathways (adjusted p-value < 0.05) in colorectal cancer in each stage. 
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that play a role in these functions (both overlap 7/21, adjusted p-value 4.94e-05, 6.77e-
06, respectively- Figure 4.5, Appendix 13, Appendix 14, Appendix 15, and Appendix 
16). 
Curiously, other functions are also significantly over-represented in all stages of CRC 
development, meaning that there are biological processes altered since early stages which 
are maintained across CRC progression. Specifically, anterograde trans-synaptic 
signaling, chemical synaptic transmission, and neuron differentiation are altered 
processes common to all stages (Figure 4.5, Appendix 13, Appendix 14, Appendix 15, 
and Appendix 16). 
 
 
4.4. Identification of potential New Biomarkers for CRC 
After identifying the genes differentially expressed and methylated in each stage of CRC, 
we were interested in assessing if they had already been associated with CRC or any other 
cancer in general. Our results showed that out of the 598 genes, 87 of them had not been 
associated neither CRC nor other cancers. On the other hand, 511 genes were mentioned 
in cancer related articles. From this set of genes, 278 also appears related with CRC 
Figure 4.5 Enriched biological process: gene ontology (GO). The top 9 more enriched 
biological processes for each stage of colorectal cancer development. Colors represent each stage 
of the disease whereas shape represents the enriched biological process. Ratio of overlapped genes 
(overlapped genes/total genes). 
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whereas 233 have not yet been associated to these terms (Figure 4.6A, Appendix 17, and 
Appendix 18). 
Then the top 20 genes most strongly associated with CRC (COMP, CD5L, CALCA, 
ACTBL2, SLC6A2, F2, KRT17, TMEFF2, ELANE, AICDA, C10orf90, PRB2, CRP, 
MMP7, KRT24, SCN11A, FOXD3, GPR149, CASR, HCRT) and the bottom 20 genes, that 
had not yet been previously associated with CRC (ADRB3, AKR1CL1, ALOXE3, ASPG, 
ASTN1, ATCAY, B3GALT1, BAI3, C13orf36, CACNG7, CADM2, CALY, CAMKV, 
CHRM2, CHST4, CHST8, CIDEA, CNGA3, CNTNAP4, and COL29A1) are shown in 
Figure 4.6B.  
 
 
4.5. Identification of genes epigenetically regulated which characterize CRC 
progression 
We then performed intersections between all genes identified as differentially expressed 
and methylated in each stage of the disease, using VennDiagram package available for R 
Figure 4.6 Potential new epigenetic biomarkers for colorectal cancer. (A) Only 14.5% of all 
genes considered as differentially expressed and methylated had not yet been previously 
associated with cancer. In contrast, 85.5% have already been reported in cancer PubMed articles. 
From these, 39.0% had not yet been reported in colorectal cancer articles whereas 46.5% were 
mentioned in “colorectal cancer” associated articles. (B) From the set of genes reported in cancer, 
we identify the top 20 genes reported in CRC (green), and 20 genes that had not been previously 
reported in CRC (red). 
57 
 
software183. The analysis showed that 85 genes are differentially methylated and 
expressed across all stages of the disease when compared to normal tissue whereas 66, 
85, 41, and 40 genes are altered only on a specific stage (stage I, stage II, stage III, and 
stage IV, respectively) of CRC development (Figure 4.7, Figure 4.8, Appendix 19, 
Appendix 20, Appendix 21, Appendix 22, and Appendix 23). 
 
 
Additionally, this approach also showed that few genes are epigenetically deregulated in 
2 or more stages. In more detail, 61, 41, and 19 genes are common to stages I and II, 
stages II and III, and stages III and IV, respectively (Figure 4.7, Figure 4.8). 
Figure 4.7 Genes epigenetically regulated across colorectal cancer development. From all 
genes found as differentially expressed and correlated to DNA methylation changes, there are 
specific set of specific genes which are differentially expressed and methylated only on stage I, 
stage II, stage III, and stage IV. Moreover, there are common set of genes that are differentially 
expressed and methylated throughout all stages. 
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Similarly, the intersection of CpG sites differentially methylated throughout CRC 
development was performed. This revealed that stage II is the stage with more CpG sites 
differentially methylated, followed by stages I, III, and IV. Specifically, 121 CpG sites 
are differentially methylated across all stages of the disease when compared to normal 
tissue (Appendix 24). 342, 815, 298, and 178 CpG sites are differentially methylated only 
on a specific stage- stage I, stage II, stage III, and stage IV, respectively (Figure 4.9, 
Appendix 25, Appendix 26, Appendix 27, , and Appendix 28). Moreover, Table 4.3 
shows the top 10 most differentially methylated CpG sites specific for each tumor stage 
when compared to normal tissue. 
 
Figure 4.8 Epigenetic dynamic in CRC. There are genes differentially expressed which present 
CpG sites differentially methylated altered in only one stage of CRC. Specifically, 66, 85, 41, 
and 40 genes revealed as differentially expressed only on stages I, II, III, and IV, respectively. 
Moreover, 61, 41, and 19 genes are common to stages I and II, stages II and III, and stages III 
and IV, respectively. Additionally, 85 genes are common to all stages of CRC (adapted from 
Chen et al. 2015). 
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Table 4.3 Top 10 specific CpG sites most differentially methylated in each stage. Positive 
values for Δβ mean that CpG site is hypermethylated in tumor tissue when compared with normal 
tissue. 
 
Interestingly, when we investigated which specific CpG sites were associated to specific 
genes, we found 200, 223, 89, and 55 CpG sites differentially methylated located within 
66, 85, 41, 40 specific genes for stages I, stage II, stage III, and stage IV, respectively. In 
regard to alterations maintained throughout CRC development, we found 121 CpG sites 
located in 55 differentially expressed genes. 
CpG Δβ  Stage Gene CpG Δβ Stage Gene 
cg01566592 0.6182190 Stage 
I 
RIMS2 cg05937969 0.4898993 Stage 
III 
CASR 
cg21769093 
-0.5632798 Stage 
I 
VWC2 cg19868631 0.4786458 Stage 
III 
VSTM2A 
cg05135828 
0.5567621 Stage 
I 
SLITRK4 cg16732616 0.4692574 Stage 
III 
DMRTA2 
cg00662647 
0.5393673 Stage 
I 
SLC35F3 cg01163842 0.4580375 Stage 
III 
GSC 
cg09813525 
0.5331854 Stage 
I 
PCDH8 cg27341472 0.4567671 Stage 
III 
TMEM196 
cg14170313 
0.5202518 Stage 
I 
RORB cg01134282 0.4539574 Stage 
III 
RALYL 
cg20129213 
0.5114721 Stage 
I 
RIMS2 cg04347874 0.4488147 Stage 
III 
NKX2-1 
cg27486637 
0.4967454 Stage 
I 
WDR17 cg23097402 0.4455062 Stage 
III 
DMRTA2 
cg17535595 
0.4963827 Stage 
I 
PCDH8 cg07961994 0.4371072 Stage 
III 
GRID2 
cg18443378 
0.4843755 Stage 
I 
WDR17 cg24882673 -
0.4334559 
Stage 
III 
ZMAT4 
cg24403845 
0.5834750 Stage 
II 
SORCS1 cg00241002 -
0.5653321 
Stage 
IV 
LOC731789 
cg16437728 
0.5450563 Stage 
II 
SYT9 cg25884711 0.5186585 Stage 
IV 
NPY 
cg25146017 
0.5413849 Stage 
II 
C6orf186 cg07369569 -
0.4910343 
Stage 
IV 
HMGCLL1 
cg25729826 
0.5324301 Stage 
II 
CASR cg02468050 0.4885486 Stage 
IV 
GRID2 
cg04842146 
0.5197947 Stage 
II 
RALYL cg01395254 -
0.4680523 
Stage 
IV 
MYT1L 
cg27361134 
0.5170881 Stage 
II 
RIMS4 cg24977670 -
0.4572511 
Stage 
IV 
CTNND2 
cg20872937 
0.5140720 Stage 
II 
GALR1 cg20388823 0.4566364 Stage 
IV 
GRID2 
cg24190603 
0.5032448 Stage 
II 
SNAP91 cg24543552 -
0.4483070 
Stage 
IV 
KHDC1L 
cg26296488 
0.5027418 Stage 
II 
DRD5 cg01847754 -
0.4460867 
Stage 
IV 
CXorf1 
cg09258813 
0.5003622 Stage 
II 
ADRB3 cg02608452 -
0.4386950 
Stage 
IV 
KCNA4 
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4.6. Potential New Biomarkers for Colorectal Cancer Diagnosis 
ROC curve analyses were performed to establish which genes and CpG sites can 
distinguish tumor tissue from normal tissue with specific sensitivity and specificity. 
Therefore, aiming to discovery which genes can be potential biomarkers to CRC 
diagnosis (AUC > 0.8), we found that 238 differentially expressed and methylated genes 
from a set of 307 can differentiate stage I tumor tissue from normal tissue (Appendix 29). 
Surprisingly, 24 genes of these genes have not yet been associated with cancer in general, 
in contrast to 214 which have already been reported in cancer (Appendix 18, Appendix 
29). From these 214 genes, 93 have not yet been reported in CRC (Appendix18, Appendix 
29). 
Figure 4.9 CpG sites differentially methylated across colorectal cancer development. A 
set of CpG sites, located in genes differentially expressed, was found differentially methylated 
in colorectal cancer. In more detail, when an overlap of these CpG sites is performed, 342, 
814, 298, and 178 CpG sites were detected as differentially methylated only on stage I, stage 
II, stage III, and stage IV, respectively. 121 were differentially methylated across all stages in 
our analysis. 
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Additionally, we intended to identify which CpG sites could potentially differentiate 
tumor from normal tissue. In accordance to our results from a set of 924 CpG sites, 835 
were able to differentiate stage I tumor tissue from normal tissue (Appendix 30). 
As an example, we show that ASTN1 is one gene which its expression values can 
differentiate stage I tumor tissue from normal tissue with an AUC of 0.989 (Figure 4.10A, 
Figure 4.10B). Additionally, previous studies have already demonstrated that ASTN1 
function is related to the nervous system. Specifically, ASTN1 is a receptor involved in 
the neuronal migration across glial fibers. A lack of these gene leads to a slow 
migration184–186. 
Interestingly, the methylation values of CpG site cg08104310 located in ASTN1 gene can 
also differentiate stage I tumor tissue from normal tissue, with an AUC of 1.000 (Figure 
4.10C, Figure 4.10D). 
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4.7. Identification of Epigenetic Biomarkers which predict patient outcome 
The prognostic value of specific genes for each stage was investigated. Thus, a survival 
analysis was performed using the median as threshold. This analysis shows that from a 
set of 85 genes altered only on stage II (Appendix 21), 6 (KRT83, LAIR2, SBSN, SNAP91, 
TMEM179, ZNF536) have statistical significance to predict the outcome of stage II CRC 
patients (Table 4.4, and Figure 4.11). Moreover, from a set of 41 specific genes altered 
only on stage III (Appendix 22), only SOX1 can predict the outcome for stage III patients 
(Table 4.4). Lastly, from a set of 40 specific genes only altered in stage IV (Appendix 
Figure 4.10 ASTN1 gene has the potential to distinguish stage I colorectal tumor tissue from 
normal tissue. (A, C) ROC curve analysis for ASTN1 expression values (AUC= 0.98), and 
cg08104310 which is located in the 3’UTR region (AUC=1.000). (B, D) Violin plots representing 
expression (FDR=1.14E-09) and methylation (FDR=9.01E-09) values for normal and tumor 
tissue. Each dot corresponds to a patient. 
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23), only 5 genes (BFSP2, F2, HOTAIR, and KHDC1L, SLC6A5) have the capability to 
predict stage IV patient outcome (Table 4.4). However, using a median of SLC6A5 
expression value to divide our patients into two distinct groups, one of them is constituted 
by only one patient. Thus, we did not consider SLC6A5 as a potential prognosis 
biomarker. 
 
Table 4.4 Genes that better predict the outcome (overall survival). HR: hazard ratio. 
 
As represented in the Table 4.4, notwithstanding stage II having more genes that can 
predict the outcome, it is in stage IV that genes have the highest statistical significance 
for that prediction. Additionally, the set of initial genes under the analysis is higher in 
stage II (85 genes) than in stage IV (40 genes). 
In Figure 4.11, are shown survival curves for ZNF536, a negative regulator of neuron 
differentiation (stage II- Figure 4.11A), SOX1, an inhibitor of cell growth and promoter 
of apoptosis (stage III- Figure 4.11B), and BFSP2, which codifies for a filament protein 
Gene Stage HR p-value Cut-off Gene Function 
SNAP91 Stage II 0.3395086 0.01277283 0.5254676 
Encodes a protein 
responsible for the 
transport of EGF receptor 
(EGFR)187. 
ZNF536 Stage II 3.1328533 0.01819290 1.7054029 
Negatively regulates 
neuron 
differentiation188,189. 
SBSN Stage II 0.3779900 0.02744733 1.2330904 
Involved in epidermal 
differentiation and  
cornified envelope 
formation190. 
KRT83 Stage II 2.5024214 0.03404451 1.0393490 
Keratin gene (RefSeq, Jul 
2008). 
TMEM179 Stage II 2.8799428 0.04846541 0.0000000 Not well established. 
LAIR2 Stage II 0.4305100 0.04998472 2.4087934 
Inhibits immune cell 
function upon collagen 
binding191. 
      
SOX1 Stage III 0.4594413 0.04070349 3.08714 
Inhibition of cell growth, 
and promotion of 
apoptosis192. 
      
KHDC1L Stage IV 0.2215415 7.522785e-04 0.0000000 
Involved in Germ Cell and 
Early Development193. 
HOTAIR Stage IV 0.3138915 1.457532e-02 2.5124539 Long noncoding RNA194. 
F2 Stage IV 3.332949 1.480315e-02 1.8856746 Coagulation factor195,196. 
BFSP2 Stage IV 2.828378 2.677998e-02 0.5357807 
Codify for a filament 
protein197. 
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(stage IV- Figure 4.11C) as examples of outcome predictors from the three stages. Those 
curves show that lower expression levels of ZNF536 (p-value=0.018, hazard ratio=3.133) 
and BFSP2 (p-value=0.027, hazard ratio=2.828) is associated with a poor prognosis 
whereas in case of SOX1 (p-value=0.041, hazard ratio=0.459) are associated with a better 
prognosis. Interestingly, neither ZNF536 nor BFSP2 have been previously reported to 
have a role in CRC. 
 
 
Furthermore, we also analyzed the potential of specific CpG sites to predict patient 
outcome and found that 88, 7, and 3 (Appendix 31, Appendix 32, and Appendix 33) from 
a set of 815, 298, and 178 CpG sites (Appendix 26, Appendix 27, and Appendix 28) are 
Figure 4.11 Epigenetically altered genes can predict patient outcome. (A) Kaplan-Meier 
curve representing the overall survival for stage II based on expression values of ZNF536 gene. 
The median cut-off-1.71 - was used to divide patients into 2 groups. (B) Kaplan-Meier curve 
representing the overall survival for stage III based on expression values of SOX1 gene. The 
median cut-off- 3.09- was used to divide patients into 2 groups. (C) Kaplan-Meier curve 
representing the overall survival for stage IV based on expression values of BFSP2 gene. The 
median cut-off-0.54 - was used to divide patients into 2 groups. The group of patients with 
expression values lower than the cut-off was considered as down-regulated (red line) whereas 
patients with expression values higher than the cut-off was considered as up-regulated (blue 
line). 
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good predictors for stage II, III, and IV, respectively. Similar to the pattern observed on 
potential gene predictors, there are more CpG sites in stage II than in any other stage. 
In addition, Figure 4.12 shows one CpG sites per stage as examples. Specifically, 
hypomethylation of cg02430935- located in the body of the tumor suppressor gene 
HMX2198 - in stage II (Figure 4.12A) and cg01847754- located in the first exon of CXorf1 
gene- in stage IV (Figure 4.12C) is associated with poor prognosis (p-value=0.013, and 
0.019, respectively; hazard ratio=3.139, and 3.155, respectively). In contrast, 
hypomethylation of cg26489108- located in the region of TSS of a gene involved in the 
regulation of  cell differentiation and survival, DMRT3199- in stage III (Figure 4.12B) is 
related to a better prognosis (p-value=0.027, hazard ratio=0.407). 
 
 
Figure 4.12 CpG sites predict patient outcome. (A) Kaplan-Meier curve representing the 
overall survival for stage II based on methylation values of cg02430935. The median cut-off-
0.63 - was used to divide patients into 2 groups. (B) Kaplan-Meier curve representing the overall 
survival for stage III based on methylation values of cg26489108. The median cut-off- 0.74- 
was used to divide patients into 2 groups. (C) Kaplan-Meier curve representing the overall 
survival for stage IV based on methylation values of cg01847754. The median cut-off-0.24 - 
was used to divide patients into 2 groups. The group of patients with methylation values lower 
than the cut-off was considered as hypomethylated (blue line) whereas patients with 
methylation values higher than the cut-off was considered as hypermethylated (red line). 
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Then, the potential of the same set of genes and CpG sites to differentiate patients that 
recurred from those who did not was also investigated. Regarding gene expression, Cox 
analysis showed that 3 genes can differentiate stage II CRC patients who recur from 
patients who do not recur (CNTD2, SNAP91, and RPH3A). In addition, 3 genes were 
identified as good predictors of recurrence for stage III (SOX1, IZUMO1, and GNGT1). 
Lastly, only 2 genes were capable to predict recurrence in stage IV (KHDC1L, and 
HTR2C; Table 4.5). 
Interestingly, SNAP91, SOX1, and KHDC1L genes can predict both overall survival and 
recurrence free survival for stage II, stage II, and stage IV, respectively (Table 4.4, Table 
4.5). 
 
Table 4.5 Genes that better predict the outcome (recurrence free survival). HR: hazard 
ratio. 
 
 
Figure 4.13 shows plotted curves representing the recurrence free survival for stages II-
IV, based on gene expression levels of CNTD2, a controller of cell cycle, SOX1, and 
HTR2C, also an intermediate of cell cycle. Remarkably, high gene expression levels of 
these 3 genes are associated with a poor prognosis, meaning that patients with high levels 
of these genes have a higher probability for recurrence. Moreover, this analysis shows 
Gene Stage HR p-value Cut-off Gene Function 
CNTD2 Stage II 0.1962451 0.0003321157 5.8719668 Controls the cell cycle
200. 
SNAP91 Stage II 0.3705250 0.0194745759 0.5066019 
Encodes a protein responsible 
for the transport of EGF 
receptor (EGFR)187. 
RPH3A Stage II 0.3897250 0.0299158467 0.6922486 
Involved in the regulation of 
exocytosis and endocytosis 
processes at presynaptic 
sites201. 
      
SOX1 Stage III 0.3592034 0.01014127 3.0871403 
Inhibition of cell growth, and 
promotion of apoptosis192. 
IZUMO1 Stage III 0.4474681 0.04563485 0.5046712 
Involved in sperm–egg 
fusion202. 
GNGT1 Stage III 0.4415817 0.04985110 1.0921398 
G-proteins of 
photoreceptors203. 
      
HTR2C Stage IV 0.2846536 0.006409629 0 
Receptor of serotonin which 
have function related to cell 
growth204,205 
KHDC1L Stage IV 0.2443717 0.007702573 0 
Involved in Germ Cell and 
Early Development193. 
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that all patients in stage IV who have expression levels of the HTR2C gene above the cut-
off recur by 3 months. In opposition, patients who have expression levels of HTR2C gene 
below the cut-off might have a delay on recurrence (Figure 4.13). 
 
 
When looking at CpG sites, in order to identify potential biomarkers for recurrence free 
survival, the same set of CpG sites tested for overall survival were also analyzed here. 
For recurrence free survival in stage II patients, it was found 30 CpG sites that can 
distinguish two groups (those who recur and those who do not recur) based on a specific 
cut-off (Appendix 34). In stage III, and stage IV, it was found 12 and 9 genes as recurrence 
predictors, respectively (Appendix 35, Appendix 36). 
Figure 4.13 Recurrence Free Survival prediction through gene expression levels. (A) 
Kaplan-Meier curve representing the recurrence free survival for stage II based on expression 
values of CNTD2 gene. The median cut-off-5.87- was used to divide patients into 2 groups. (B) 
Kaplan-Meier curve representing the recurrence free survival for stage III based on expression 
values of SOX1 gene. The median cut-off-3.09 - was used to divide patients into 2 groups. (C) 
Kaplan-Meier curve representing the recurrence free survival for stage IV based on expression 
values of HTRC2 gene. The median cut-off-0 - was used to divide patients into 2 groups. The 
group of patients with expression values lower than the cut-off was considered as down-
regulated (red line) whereas patients with expression values higher than the cut-off was 
considered as up-regulated (blue line). 
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Figure 4.14 shows Kaplan-Meier plots representing recurrence free survival curves for 
the most significant CpG site from each stage. Specifically, high methylation levels of 
cg06162589- located in the 3’UTR region of a tumor suppressor gene SLC5A8206 - in 
stage II (p-value=0.0066, hazard ratio= 0.2924- Figure 4.14A) and cg03700449- located 
in the first exon of a gene involved in the neurogenesis, ASCL1207- in stage III (p-
value=0.0055, hazard ratio= 0.3114- Figure 4.14B) are associated with a poor prognosis 
whereas high methylation levels of cg14772660- located in body of a gene SLC5A7 that 
encodes to a choline transporter208- in stage IV (p-value=0.0047, hazard ratio= 4.3174- 
Figure 4.14C) are associated with a better prognosis. 
Moreover, this analysis also showed that patients with high methylation levels of 
cg06162589, have a probability of 100% to recur at 7 months. In contrast, patients who 
present low methylation levels of that CpG site have a reduced probability to recur 
(Figure 4.14A). A similar scenario happens in stage IV, when methylation levels of 
cg14772660 are considered. Specifically, it is expected that all patients of both 
hypomethylated and hypermethylated groups recur. However, patients who present low 
methylation levels of cg14772660 recur before (Figure 4.14C). 
69 
 
 
 
4.8. CRC patients can be grouped according to their gene expression and 
DNA methylation patterns 
Here, in order to validate the results obtained by our pipeline (Erro! A origem da 
referência não foi encontrada.), we used the HJ-biplot multivariate technique of 
graphical representation, followed by hierarchical clustering in the patient coordinates, 
considering the ward method and the Euclidean square distance. Furthermore, this 
approach was also used aiming to corroborate the pipeline and to distinguish groups of 
patients classified within the same stage. In order to facilitate the visualization of the 
results we established three groups per stage and selected genes and CpG sites with 
contributions over than 0.7 to increase powerful quality contributions to HJ-biplot 
(Figure 4.15, Figure 4.16). 
Figure 4.14 CpG sites can predict recurrence. (A) Kaplan-Meier curve representing the 
recurrence free survival for stage II based on methylation levels of cg06162589. The median cut-
off-0.32- was used to divide patients into 2 groups. (B) Kaplan-Meier curve representing the 
recurrence free survival for stage III based on methylation levels of cg03700449. The median 
cut-off-0.52 - was used to divide patients into 2 groups. (C) Kaplan-Meier curve representing 
the recurrence free survival for stage IV based on methylation levels of cg14772660. The median 
cut-off-0.69 - was used to divide patients into 2 groups. The group of patients with methylation 
values lower than the cut-off was considered as hypermethylated (red line) whereas patients with 
methylation values higher than the cut-off was considered as hypomethylated (blue line). 
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Firstly, we analyzed how samples from CRC patients are distributed based on genes 
differentially expressed in each stage when compared to normal tissue samples. Applying 
the contribution cut-off, we selected 43, 22, 12, and 12 genes (from a set of 307, 400, 305, 
and 233, respectively) from stages I, II, III, and IV. This suggests that each set of variables 
is the strongest when combining genes responsible for the patient distribution in a 
respective stage. 
Since the HJ-biplot is a data reduction technique, the plans 1-2 (Figure 4.15) retains 
87.3%, 85.4%, 87.4%, and 89.5% of the total absorbed inertia (Figure 4.15A, Appendix 
37, Figure 4.15B, Appendix 38, Figure 4.15C, Appendix 39, Figure 4.15D, and 
Appendix 40) from stages I, II, III, and IV, respectively. This fact shows that all genes in 
all stages are correlated and represent high levels of information (amount of accumulated 
variance). We also observed that no isolated gene (or a set of genes) exists with other 
behavior (correlated with axis 2). In fact, all of these set of variables are correlated to the 
axis 1, meaning that all variables are correlated with each other. 
Moreover, this approach shows that we can distinguish primary tumor from normal 
samples (circles and triangles, respectively- Figure 4.15). Thus, the pipeline applied was 
efficient. Also, it is also possible to identify two subgroups of primary tumor samples (red 
and green), suggesting that in the same stage, there are patients who have different 
patterns of gene expression, and might be responsible for different outcomes (Figure 
4.15). Curiously, when we looked at the HJ-biplot representation of each stages, we 
observed that the distance between normal and primary tumor samples is bigger in stages 
I and IV. This fact shows that in these stages primary tumor samples are more distinct 
from normal samples than in other stages. Interestingly we observed two-subgroups of 
patients at stage II where the green subgroup is closer to normal tissue when compared to 
the red group. At a lesser extent the same was observed in stage III of the disease 
suggesting that different set of genes are characterizing distinct subgroups of patients. 
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The same approach was applied using CpG sites differentially methylated in CRC. For 
that we selected 116, 65, 16, and 30 from stages I, II, III, and IV, respectively. The total 
absorbed inertia of plans 1-2 were: 85.3%, 81.3%, 84.4%, and 85.2% for each stage 
(Figure 4.16A, Appendix 41, Figure 4.16B, Appendix 42, Figure 4.16C, Appendix 43, 
Figure 4.16D, and Appendix 44). These results are similar to the ones obtained for gene 
expression since all differentially methylated CpG sites are correlated and also represent 
high levels of retained information. We also observed that no isolated CpG sites 
correlated with axis 2 exist, meaning that all of those CpG sites are correlated. 
Figure 4.15 HJ-biplot representation of gene expression for (A) stage I, (B) stage II, (C) stage 
III, and (D) stage IV of CRC. In stage I, cluster 1 is composed by 25 patients, cluster 2 by 29 
patients and cluster 3 by 21 patients. In stage II, cluster 1 is composed by 103 patients, cluster 2 
by 25 patients and cluster 3 by 24 patients. In stage III, cluster 1 is composed by 46 patients, 
cluster 2 by 62 patients and cluster 3 by 21 patients. In stage IV, cluster 1 is composed by 32 
patients, cluster 2 by 18 patients and cluster 3 by 22 patients. 
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Furthermore, similar to the observed in HJ-biplot applied to a set of genes, we found that 
the set of selected CpG sites can also differentiate primary tumor from normal samples 
(circles and triangles, respectively), and it can divide primary tumor samples into two 
distinct groups (red and green). Additionally, it is also possible to observe that the 
distance from the cluster constituted by normal samples (triangles) to the clusters 
constituted by primary tumor samples is higher in stages I, and IV when compared to 
stages II, and III (Figure 4.16). This suggests that the set of CpG sites selected can easily 
detect which are the tumor samples. Regarding to stage II, we detected a decrease of the 
proximity between clusters of normal and primary tumor samples (Figure 4.16B). As for 
stage III, we found that the cluster formed by normal samples are homogenous, in spite 
of the proximity to other clusters constituted by primary tumor samples, suggesting that 
there are tumor samples with more similarities to normal samples. (Figure 4.16C). 
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Figure 4.16 HJ biplot representation of DNA methylation for (A) stage I, (B) stage II, (C) 
stage III, and (D) stage IV. In stage I, cluster 1 is composed by 27 patients, cluster 2 by 25 
patients and cluster 3 by 23 patients. In stage II, cluster 1 is composed by 91 patients, cluster 2 
by 36 patients and cluster 3 by 25 patients. In stage III, cluster 1 is composed by 29 patients, 
cluster 2 by 81 patients and cluster 3 by 22 patients. In stage IV, cluster 1 is composed by 30 
patients, cluster 2 by 19 patients and cluster 3 by 23 patients. 
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5. CHAPTER V- DISCUSSION 
In this study, we performed a whole-genome analysis of the CRC patient cohort, available 
at the TCGA dataset, with the intention of identifying epigenetic signatures during CRC 
development. Contrarily to the majority of whole-genome analysis performed, we 
decided to analyze CRC initiation and progression, by distributing our patients through a 
correspondent TNM stage209–211. 
We found that epigenetic alterations are present throughout CRC development and that 
they can be associated either to the overexpression or silencing of genes. This was 
expected since DNA methylation alters the chromatin structure212,213. In addition, the 
dynamics of epigenetic alterations was also shown here, since there are different DNA 
methylation patterns in different stages of CRC development. Thus, as previous studies 
reported, understanding DNA methylation alterations may provide new insights on this 
disease, and hopefully help to improve both diagnostic and prognostic in CRC214. Indeed, 
it is known that epigenetic changes are dynamic during events as embryonic development 
and cell differentiation. However, until now there was a lack of studies that demonstrated 
these dynamics across CRC initiation and progression215–217. 
Moreover, we also found that there are groups of genes more affected by these changes 
than others, possibly due to the importance of specific classes of genes involved in cancer 
initiation and progression7. However, few genes are epigenetically altered in all stages of 
CRC suggesting that, depending on the CRC stage, different genes need to be 
overexpressed or down-regulated in order to favor the disease91. 
Furthermore, applying the developed pipeline, we found that stage IV contains less 
alterations, where DNA methylation is correlated with gene expression, than the other 
stages when compared to normal tissue. One possible explanation for this observation is 
that in the last stage, cells may not need to express genes responsible for cancer initiation. 
However, another reasonable hypothesis lies on the fact that during metastastatic 
formation, cancer cells might need to become more similar to normal cells for this process 
to be successful. Alternatively, sample size could have had an influence in our analysis. 
Moreover, we also found that stage I is not the stage with more alterations, in opposition 
to previous reports81. This difference can also be explained by sample size. Additionally, 
previous studies also shown that, although there are no significant differences in the 
proportion of early and advanced tumors which present aberrant DNA methylation 
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patterns, the number of genes differentially methylated is different across cancer initiation 
and progression81,218,219. 
This study identified for each stage of CRC development, multiple CpG sites 
differentially methylated which are correlated to alterations in gene expression. In 
agreement with previous studies220, when we investigated where these CpG sites are 
located, we found that promoters (TSS200, TSS1500) and gene body are the regions more 
affected by aberrant methylation. Indeed, the aberrant methylation in promoter region 
alters the accessibility of transcriptions factors to the DNA, leading to changes in gene 
expression127. Additionally, gene body methylation has already been associated to 
alteration on gene expression221. Recently, it was reported that intragenic DNA 
methylation can prevent the transcription initiation of aberrant transcripts in mouse 
embryonic stem cells222. Another study also suggested that gene body DNA methylation 
associated with H3K36me3 blocks aberrant transcription223. 
Moreover, when we compared methylation patterns across CRC progression, we found 
that the most common alteration is hypermethylation. Among all hypermethylated CpG 
sites, we observed that the great majority is located in down-regulated genes, meaning 
that high methylation levels are associated to low gene expression levels. This fact further 
strengthens the conventional idea that hypermethylation is often associated with down-
regulation whereas hypomethylation leads to gene activation. However, there are cases 
where this is not verified. Indeed, the consequence of DNA methylation in gene 
expression depends on its location in the gene. Specifically, when CpG sites are located 
in repressor regions, and this region is hypermethylated, repressors are blocked. 
Consequently, hypermethylation will be associated with overexpression of the respective 
gene. Interestingly, this pattern was observed before in genes involved in cancer as TERT 
and EGFR. In both cases, promoter hypermethylation leads to gene activation127,224. 
Nevertheless, the pattern described before is less observed in stage IV. Specifically, in 
opposition to previous stages, hypomethylation is more common than hypermethylation 
and a positive correlation between DNA methylation and gene expression levels in tumor 
tissue is also more common than negative correlation. These findings suggest that the 
epigenetic pattern of stage IV is different from other stages. Importantly, across cancer 
progression, the heterogeneity increases, which can instigate this difference225. 
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When the top 15 most differentially expressed genes with significant differences in DNA 
methylation were analyzed, we found that the vast majority were simultaneously present 
in the top 15 in all four stages. Specifically, genes as ZIC5, DIRC1, KRTAP3-1 are found 
in all stages, meaning that these genes are among the most differentially expressed genes 
in CRC progression. Curiously, ZIC5 is a zinc finger complex which has already been 
associated with cancer. Satow et al. also associated ZIC5 with higher survival of CRC 
cells by enhancing FAK and STAT3 activity226. DIRC1 is not well described, although it 
has been reported in familial clear cell renal cancer227. KRTAP3-1 is a keratin-related 
gene, and has not been previously reported in cancer PubMed articles228. Although these 
three genes are players in CRC their role has not yet been characterized. 
Furthermore, FEZF1, SOX14, LOC84931, and PGLYRP3 are among the top 15 most 
differentially expressed genes with significant differences in methylation in stages I, II, 
and III. All these genes have been associated with cancer, however only FEZF1 was 
previously reported in CRC. Interestingly, both FEZF1 and SOX14 are reported as 
enhancers of tumor proliferation and metastasis229,230. LOC84931 has also been 
associated with cancer, however its role in oncogenesis is poorly described231. At last, 
Jing et al. have associated PGLYRP3 to inflammatory bowel disease (IBD)232. 
Importantly, higher risk of CRC is mostly connected to IBD233,234. This fact suggests that 
PGLYRP3 can be effectively related to CRC directly or indirectly, although its association 
has not been yet well studied. 
Biological process analysis was performed using KEGG and GO platforms. Results 
indicate that genes differentially expressed and methylated across CRC development have 
similar functions, being the majority related to the nervous system development. 
Specifically, KEGG pathway analysis revels “nicotine addiction”, “neuroactive ligand-
receptor interaction”, “cAMP signaling pathway”, “salivary secretion” and “ALS” as the 
most enriched pathways in CRC. Previous studies have reported that smoking is strongly 
associated with higher incidence and mortality in CRC235–238. “Neuroactive ligand-
receptor interaction” pathway also revealed to be important. This pathway was also found 
enriched in other types of cancer as well as in CRC239,240. Moreover, several studies have 
also described the relationship between cAMP and cancer. Specifically, studies referred 
that increasing cAMP levels leads to inhibition of cell growth by the induction of 
apoptosis and/or cell cycle arrest241. For example, Dong, H et al. have demonstrated that 
the activation of cAMP signaling leads to a decrease of cell migration in breast cancer242. 
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Regarding the salivary secretion pathway, there are reports which suggest that cancer can 
interact with salivary glands, including pancreatic cancer, breast cancer, lung cancer, and 
ovarian cancer. However, these relationship is not yet well established243. Finally, the 
ALS pathway is also enriched in our analysis. Curiously, neurodegenerative diseases have 
been inversely associated with cancer244–246. Whereas cancer involve resistance to cell 
death, neurodegenerative diseases occurs due to premature cell death247. In case of ALS 
pathways, its relationship with cancer is not clear248,249. 
Interestingly, GO biological process analysis shows that the most enriched functions are 
related to the neural system. Several studies suggested that there is a crosstalk between 
neural system and CRC cells. Neurogenesis and axogenesis are important in cancer 
development, and nerves are constituents of the microenvironment250–252. In addition, 
studies suggested that neurotransmitters can stimulate migration, cell survival, and 
proliferation, immune suppression, angiogenesis, and provide mechanical support. Hence 
the nervous system pathways development is associated with poor prognosis, by inducing 
tumorigenesis and metastasis253–255. For example, in pancreatic cancer, cancer cells grow 
and invade nerves, leading to a poor prognosis and severe pain256,257. In a specific case of 
CRC progression, there are also evidences that the nervous system support cell migration 
through a processes called perineural invasion258. 
Unexpected, from all genes found as differentially expressed and methylated, 14.5% have 
not yet been previously reported in any cancer type, including CRC and might be critical 
to CRC initiation and progression. For example, CIDEA has already been associated with 
other cancers by promoting apoptosis in mammalian cells259. Interestingly, our analysis 
showed that this gene is differentially expressed, and it has CpG sites differentially 
methylated in all stages of CRC progression. Furthermore, CIDEA is down-regulated in 
all stages, which is corroborated by its biological function259. 
Then, we investigated the potential of genes differentially expressed and methylated 
between stage I and normal tissue as potential diagnostic biomarkers in CRC. This 
analysis revealed that 78% of differentially expressed genes and 90% of CpG sites 
differentially methylated are good candidates. This evidence suggests that DNA 
methylation levels of CpG sites can probably be more trustworthy than gene expression 
levels in relation to diagnosis. This because almost all CpG sites found differentially 
methylated in tumor tissue when compared to normal tissue could be used as potential 
biomarkers for diagnosis in contrast to the lower number of differently expressed genes 
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with the same ability One possible explanation to this fact might be due to expression 
levels being more instable, meaning that they can vary easily due to different factors 
besides cancer260. Moreover, these are good early diagnostic candidates, since its 
methylation occurs in early stages of CRC. For example, ASTN1 where both gene 
expression and DNA methylation values could differentiate stage I tumor tissue from 
normal tissue, had a higher AUC value for the methylation of one of its CpG cg08104310, 
rather than for its expression values. This result suggests that methylation of ASTN1 gene 
can better differentiate tumor from normal tissue than its expression levels. ASTN1 
codifies for a membrane protein involved in the central nervous system development261. 
Interestingly, functions related to nervous system development are enriched in our 
analysis and have been associated with cancer, as reported before. 
Additionally, this analysis showed that although enriched functions of genes differentially 
expressed with probes differentially methylated are similar across CRC, there are 
different genes associated to CRC initiation and progression. The same pattern was 
observed with specific CpG sites that were associated only to a specific stage, as well as 
CpG sites which characterize all stages of CRC development. Also, we found that there 
are genes differentially expressed and with probes differentially methylated in specific 
stages of CRC development, suggesting that these genes have an important function in a 
specific stage. In contrast, we also found genes differentially expressed and methylated 
in all stages, evidencing that there are genes that play a role across CRC development. It 
was also identified common genes between two stages suggesting a role in the transition 
between stages. Interestingly, there is a lack of studies that corroborate these findings, as 
the vast majority of whole-genome analysis performed until this date do not analyze DNA 
methylation and gene expression data across cancer initiation and progression taking into 
account the TNM staging. 
Also, when we evaluated the potential of specific genes differentially expressed to predict 
the outcome of patients in stage II, III, and IV, we found that there are genes capable of 
distinguishing two groups depending on a gene expression cut-off value. For example, in 
stage II, ZNF536 expression values can differentiate two distinct groups. In this case, the 
down-regulation of ZNF536 is associated with poor prognosis. Interestingly, this gene 
encodes for a zinc finger protein which negatively regulates neuron differentiation188,189 
and was previously reported in association with cancer only once. Importantly, this type 
of proteins have been revealed as players in the progression of multiple cancer types262.  
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Regarding stages III and IV, genes as SOX1 and BFSP2, respectively, can also 
differentiate two groups with distinct outcome. Indeed, higher gene expression levels of 
SOX1 were associated with a worst prognosis. Paradoxically, distinct studies reported that 
SOX1 is associated with inhibition of cell growth as well as promoting apoptosis, by 
decreasing β-catenin levels192. Hence, it was expected that low methylation values of 
SOX1 were associated with a worst prognosis. Interestingly, DNA methylation changes 
have also been reported in another study, where SOX1 was hypermethylated in CRC. In 
the same study, SOX1 was also found most significantly methylated in later stages of 
TNM classification263. 
Furthermore, BFSP2 is a gene that codifies for a filament protein and lower BFSP2 
expression levels are associated with poor prognosis in this study. Interestingly, this gene 
has not been previously reported in CRC, perhaps due to their specificity to lens fiber 
cells, a structure in the eye197. 
Next, we evaluated the potential of CpG sites to predict patient outcome and found that 
there are CpG sites efficient to distinguish 2 groups. Specifically, CpG sites as 
cg02430935, cg26489108 and cg01847754 are able to predict the outcome in stage II, 
stage III, and stage IV, respectively. Furthermore, both cg0243093- located in the first 
intron of HMX2 gene- and cg26489108- located in the region near to the TSS of DMRT3 
gene- are hypermethylated in tumor tissue (stages II and III, respectively). Moreover, 
HMX2 gene was down-regulated, and DMRT3 gene was up-regulated. In addition, 
previous studies have reported that HMX2 inhibits the cellular growth, and are frequently 
silenced in colorectal cancer cell lines and primary tumors123. DMRT3 was also found up-
regulated in a recent study. The same study has reported an interaction between this gene 
and both TP63 and SOX2 in lung cancer. 
Interestingly, hypermethylated of cg0243093 (HMX2 gene) in tumor tissue is associated 
with a better prognosis in stage II patients. In fact, previous studies have suggested that 
HMX2 has tumor suppressor activity in cancer198, being down-regulated in other cancer 
types123. 
Regarding to cg26489108 (DMRT3 gene), we found a positive correlation between 
methylation levels of this CpG site and DMRT3 gene in tumor tissue which is associated 
with poor prognosis. However, in contrast with the standard epigenetic regulation 
mechanism, hypermethylation of this CpG site is associated with gene over-expression264. 
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One possible explanation for this, is that this CpG site is located in a repressor binding 
region. When hypermethylation occurs, the repressors are blocked, and, consequently, 
the gene is constitutively expressed. The hypothesis that hypermethylation leads to the 
activation of an alternative promoter should be considered127.  
Considering cg01847754- located in the first exon of CXorf1 gene is hypomethylated in 
stage IV. This is in accordance with survival analysis performed, which showed that low 
methylation levels are associated with a poor prognosis. Interestingly, one more time, the 
canonical pathway is not observed, meaning that hypomethylation of cg01847754 is 
associated with down-regulation of CXorf1 gene. Indeed, this gene may be an interesting 
candidate biomarker for cancer prognosis although its role in cancer is not clear yet. 
Then, were identified genes that could predict patient recurrence. CNTD2, SOX1, and 
HTR2C are some of the genes found as predictors of recurrence free survival in stages II, 
III, and IV, respectively. Specifically, CNTD2 was found over-expressed in stage II CRC 
tissue which is in agreement with a poor prognostic associated with high gene expression 
levels. CNTD2 is a member of the cyclin family which can control the cell cycle. When 
there are alterations on genes that regulate the cell cycle, the consequence may be 
uncontrolled cell growth. Recently, this gene was reported as a new oncogenic driver in 
lung cancer200. 
HTR2C is up-regulated in stage IV of our cohort, and, as expected, high expression levels 
of this gene are associated with a poor prognosis. In agreement with our finding, other 
studies have already reported an over-expression of HTR2C in tumor tissue204. 
Interestingly, HTR2C is a receptor of serotonin involved in cell growth204,205. Also, there 
are evidences that serotonin plays a key role in aggressive tumors, mainly when HTR2C 
is present205. 
We also observed that high SOX1 expression levels in stage III is associated with a poor 
prognosis. Similar to SOX1, SNAP91, and KHDC1L were found to be predictors of both 
survival and recurrence for CRC patients in stages II, and IV, respectively. This suggest 
that the expression levels of these genes should be monitored even after cancer treatment. 
Moreover, SOX1, and SNAP91 were also identified as correlated with survival in different 
types of cancers including glioblastomas265–267. Additionally, studies reported aberrant 
methylation of SOX1 in a CRC cohort, validating our results263. Regarding to KHDC1L, 
there are no reports associating it neither to CRC nor to cancer in general. 
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Furthermore, our findings revealed that there are CpG sites that allow to differentiate 
patient recurrence. For example, cg06162589 located in the 3’UTR of SLC5A8, 
cg03700449 located in the first exon of ASCL1, and cg14772660 located in the gene body 
of SLC5A7 are CpG sites with potential for prognosis in stage II, III, and IV, respectively. 
Moreover, both cg06162589 and cg14772660 are hypomethylated, and positively 
correlated with gene expression levels of tumor tissue, whereas cg03700449 is 
hypermethylated, and negatively correlated with gene expression levels of tumor tissue. 
In addition, Cox analysis reveals that low methylation levels of cg14772660, and high 
levels of cg03700449 are associated with poor prognosis, regarding recurrence free 
survival. Although cg06162589 is hypomethylated in tumor tissue, low methylation 
levels are associated with a better prognosis of CRC patients. In addition, SLC5A8 was 
also identified as down-regulated in colon and other tumors as lung cancer and acute 
myeloid leukemia268–270. In hepatocellular carcinoma, SLC5A8 was also found to be 
down-regulated, which was associated with the inhibition of cancer progression by 
decreasing the expression of proteins such as β-catenin, and c-Myc271. Interestingly, in 
previous studies SLC5A8 has already been reported as a tumor suppressor gene that can 
be silenced by epigenetic mechanisms206,269,270,272–275. In lung adenocarcinomas, ASCL1, 
a gene involved in cell proliferation, survival, and cell cycle control, was found 
overexpressed mainly in smokers, and associated with a poor prognosis. Additionally, in 
the same study it was observed a global hypomethylation of this gene276. Other studies 
have also reported that DNA methylation regulates expression levels of ASCL1 in cancer. 
Interestingly, in medullary thyroid cancer, the expression levels of this gene are decreased 
by the action of NOTCH1277. Moreover, SLC5A7 was also found to be down-regulated in 
different tumor types, being associated with poor prognosis. In contrast, high expression 
levels of this gene are associated with better prognosis in several cancer types. However, 
its role in cancer development remains unclear278. 
Finally, using HJ-biplot multivariate analysis we identified a set of gene expression and 
methylation profiles that can differentiate normal and tumor samples corroborating the 
pipeline previously applied. Also, this analysis allowed to differentiate for each tumor 
stage two different sub-groups suggesting that there are patients who are classified into 
the same stage but have distinct gene expression and methylation patterns. Indeed, this 
might explain why patients at the same stage differ in survival time. However, to validate 
these results, further studies need to be performed. Specifically, to evaluate whether, in 
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fact, the outcome of these two groups are distinct, a Kaplan-Meier analysis followed by 
a logrank test can be performed.  
In summary, epigenetic changes are dynamic across CRC initiation and progression, and 
can influence the expression of genes involved in this process, including genes with 
functions related to the nervous system regulation. Using specific cut-offs for certain 
differentially expressed genes or differentially methylated CpG sites, it was possible to 
distinguish tumor from normal tissue, in an early stages of the disease (stage I), and 
determine patient outcomes (overall survival and recurrence free survival). 
 
5.1. Limitations 
The current study presents some limitations including: 
a. The sample size should be larger and similar for each stage. 
b. Normal samples are from tumor adjacent tissues and, in some cases, they might 
not be normal anymore. It would be better to have normal tissue from individuals 
without disease. 
c. The clinical information should be more robust as the current one presented some 
difficulties to standardize our groups. 
d. In the HJ-biplot representation, it was only taken in account both first and second 
dimensions. 
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6. CHAPTER VI- CONCLUSION 
This whole-genome analysis provides advances in the knowledge of epigenetic dynamics 
across CRC initiation and progression. 
Here, we created an epigenetic roadmap, identifying new biomarkers for CRC that can be 
potentially used in the clinic for CRC detection and prediction of survival and recurrence. 
Firstly, we defined a pipeline based on a statistical analysis to identify which genes and 
CpG sites are differentially expressed and methylated in each TNM stage of tumor tissue, 
when compared to normal tissue. 
Epigenetic alterations are present in CRC progression although only 85 genes with 
significant different expression profiles are common to all stages of CRC progression. 
Interestingly, we also found expression and methylation profiles specific to different 
stages of CRC. 
Moreover, this specific expression and methylation profiles can distinguish two sub-
groups of patients with distinct outcomes at the same cancer stage.  
Additionally, we have identified genes differentially expressed with CpG sites 
differentially methylated in CRC that have never been reported to be associated to CRC 
or cancer in general.  
Furthermore, our multivariate analysis showed that our pipeline was efficient in 
distinguishing tumor from normal samples and that a small set of genes with distinct 
expression and methylation profiles can distinguish different subgroups of patients in the 
same tumor stage. 
In conclusion, our findings evidence that epigenetic alterations are dynamic across CRC 
initiation and progression and may have clinical applications. 
However, further analyzes are needed. In the future, these findings should be validated in 
other cohorts, including cohorts with a larger sample size for each stage.  
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